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The grading of facial appearance and function in peripheral facial palsy (FP) is 
inconsistent and a subject of much dispute. We assessed two grading scales to determine 
whether one might be superior for use in everyday clinical practice (I). Eight video-
recorded FP patients were graded in two sittings by 26 doctors. Repeatability and 
agreement for the Sunnybrook facial grading system (SFGS) were measured by 
intraclass correlation coefficient and coefficient of repeatability, and for the House-
Brackmann facial grading system (H-B FGS) by agreement percentage and kappa 
coefficients.  
 
Repeatability for SFGS proved to be from good to excellent and for H-B FGS from fair 
to good depending on the statistical method used (I). Agreement between doctors for 
SFGS was from moderate to excellent and for H-B FGS from poor to fair. Because 
SFGS was at least as good in repeatability as H-B FGS and showed more reliable results 
in agreement between doctors, we encourage the use of SFGS over H-B FGS. 
 
The etiology of acute peripheral FP is unverified, as is the question of whether the 
central nervous system is affected at some phase of the disease. Our objective was to 
determine whether herpesviral DNA could be found in cerebrospinal fluid (CSF) of 
peripheral FP patients (II, III). CSF samples from 33 peripheral FP patients (34 
samples) and 36 controls were retrospectively examined for DNA of herpes simplex 
virus-1 (HSV-1), varicella-zoster virus (VZV), and human herpesvirus-6 (HHV-6) by 
polymerase chain reaction (PCR) (II) and for DNA of HSV-1 and -2, VZV, HHV-6A, 
-6B, and -7, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) by multiplex-PCR 
and oligonucleotide microarray methods (III).  
 
Three patients and five controls had HHV-6 or -7 DNA in CSF (II, III). No DNA of 
HSV-1 or -2, VZV, EBV, or CMV was found. HHV-6 and-7 DNA was detectable in 
about 10% of the CSF samples evaluated from immunocompetent adolescents and 
adults without severe disease (III), an important finding that indicates caution when 
interpreting CSF results. Detecting HHV-7 and dual HHV-6A and -6B DNA in CSF of 
FP patients is intriguing, but these DNA findings in association with FP and the other 
diseases that they accompanied require further exploration. 
 
Melkersson-Rosenthal syndrome (MRS) is classically defined as a triad of recurrent 
labial or oro-facial edema, recurrent peripheral FP, and plicated tongue. All three signs 
are present in the minority of patients. Edema-dominated forms are more common in the 
literature, while MRS with FP has received little attention. The etiology and true 
incidence of MRS are unknown. We investigated characteristics of MRS with FP (IV) 
and also compared MRS patients treated at the Departments of Otorhinolaryngology 
and Dermatology. We hypothesized that in MRS FP patients edema would not be the 
dominating feature, nor would progression with time occur, contrary to existing 
knowledge. Patient charts at both departments were evaluated for MRS. Patients with 
FP were mailed a questionnaire and clinically examined. When appropriate, a tissue 
biopsy was taken to search for the nonnecrotizing granulomatous infiltrations typical of 
MRS. Herpesviruses, among many other possibilities, have been suspected as etiologic 
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factors in MRS. We searched peripheral blood DNA for gene mutations leading to 
UNC-93B protein deficiency, which would predispose to HSV-1 infections. 
 
Thirty-five MRS patients were found, 20 with FP and 11 with the triad form of MRS. 
At the Department of Otorhinolaryngology, every MRS patient had FP. Two had tissue 
biopsies taken during an acute edema episode, with nonnecrotizing granulomatous 
findings. Edema in most MRS FP patients did not dominate the clinical picture, and no 
progression of the disease was observed, consistent with our hypotheses. Two triad 
patients had recurring anterior uveitis. No UNC-93B1 gene mutations were found. At 
the Department of Dermatology, two patients had triad MRS and 15 had 
monosymptomatic granulomatous cheilitis with frequent or persistent edema and typical 
MRS tissue histology. The clinical picture of MRS varied according to the department 
where the patient was treated. More studies from otorhinolaryngology departments and 
on patients with FP would clarify the actual incidence and clinical picture of the 
syndrome.  
 






AAO-HNS American Academy of Otolaryngology-Head and Neck Surgery  
CG  cheilitis granulomatosa 
CI  confidence interval  
CMV  cytomegalovirus 
CNS  central nervous system 
CR  coefficient of repeatability 
CSF  cerebrospinal fluid 
EBV  Epstein-Barr virus 
ENoG  electroneuronography 
FP  facial palsy 
H-B FGS House-Brackmann facial grading system 
HHV  human herpesvirus 
HSV  herpes simplex virus 
ICC  intraclass correlation coefficient 
LP  lingua plicata 
MRS  Melkersson-Rosenthal syndrome 
PCR  polymerase chain reaction 
SD  standard deviation  
SFGS  Sunnybrook facial grading system 
VP  virus particle  
VZV  varicella-zoster virus 





Peripheral facial palsy (FP) is a common condition, in most cases without known cause. 
Being clearly visible, the cosmetic drawback for the patient is obvious, as is the inability 
to mimic normal communication, but the effects on vision, eating, and drinking are 
easily overlooked. Even though most patients recover, outcome is not predictable at 
palsy onset. Patients are typically under great psychological stress in addition to their 
physical limitations. Not knowing the cause, no effective treatments exist to offset 
sequelae or persistent palsy in the approximately 30% of patients who fail to recover 
completely (Peitersen 2002). Grading facial function is necessary for determining and 
reporting the spontaneous course of FP and especially the results of medical or surgical 
treatments. However, FP studies are hindered by the lack of an objective, standardized 
evaluation method. The subjective methods used vary and are prone to intra- and 
interrater variation. 
 
The etiology of acute idiopathic peripheral FP (Bell’s palsy) is still under debate 
although herpesviruses, especially herpes simplex virus-1 (HSV-1) and varicella-zoster 
virus (VZV), have gained support as etiologic factors (Furuta et al. 2000). HSV-1 
reactivation has been reported to accompany Bell’s palsy, but causality is uncertain 
(Murakami et al. 1996). VZV is known to cause Ramsay Hunt syndrome, a peripheral 
FP with herpes vesicles most commonly in the ear or mouth. In Ramsay Hunt 
syndrome, VZV is assumed to be able to spread widely in neural and mucocutaneous 
tissue and in cerebrospinal fluid (CSF) (Murakami et al. 1998). VZV infection may 
present without visible vesicles as zoster sine herpete, and has been suspected to be a 
causative agent in Bell’s palsy in up to 30% of cases (Furuta et al. 2000). Human 
herpesvirus (HHV)-6 and -7 infections occur commonly in early childhood and the 
viruses persist latently after primary infection (Ward 2005). Both HHV-6 and -7 have 
been detected in normal brain tissue at autopsy, indicating that they are able to invade 
and persist asymptomatically in the central nervous system (CNS) and can be expected 
to reactivate occasionally (Chan et al. 2000, Ward 2005). HHV-6 and -7 have seldom 
been studied in association with FP, but we previously found HHV-6 DNA in the tear 
fluid of Bell’s palsy patients more often than in controls and treated a toddler with FP 
following exanthem subitum, a childhood rash caused by HHV-6 or -7 (Pitkäranta et al. 
2000, Pitkäranta et al. 2004). CSF studies on FP patients are scarce and especially rare 
for HHV-6 and -7. 
 
Melkersson-Rosenthal syndrome (MRS) is another entity of peripheral FP of unknown 
etiology. In triad form, it consists of recurrent peripheral FP, recurrent oro-facial 
edemas, and plicated tongue (lingua plicata, LP). All symptoms are not needed for 
diagnosis, and they most often occur on separate occasions (Hornstein 1997). As a rare 
syndrome, studies on MRS are scarce, mainly concentrating on patients with edema 
dominating the clinical picture, and studies from otorhinolaryngology departments and 
on patients with FP are few. MRS is thought to be multifactorial in origin and based on 
hereditary predisposition (Meisel-Stosiek et al. 1990). Many etiologic factors are 




The objective of this study was to assess the utility of two subjective facial grading 
systems, to evaluate the etiologic role of human herpesviruses in peripheral FP, and to 
explore characteristics of MRS. 
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REVIEW OF THE LITERATURE 
 
 
Peripheral facial palsy 
 
The facial nerve, the seventh cranial nerve, has its nuclei in the pons of the brainstem 
(Fig. 1) (May 2000). Nerve function disturbance at this level or distal to it, may lead to 
ipsilateral peripheral FP (Fig. 2), which affects voluntary and involuntary movements of 
all facial muscles. Muscles involved in raising and wrinkling the forehead and closing 
the eyes are bilaterally innervated proximal to the facial motor nucleus in the pons, and 
thus, function disturbances in cortical areas result in central FP, where the lower facial 
muscles are affected, but the forehead and eyes are spared, unlike in peripheral FP (Fig. 
2) (May 2000). The facial nerve also carries parasympathetic fibers to the salivary and 
lacrimal glands, taste fibers to the anterior two-thirds of the tongue, other sensory fibers 
to mucous membranes of the pharynx, nose, and palatine, and less well-defined sensory 
fibers to the skin of the external auditory canal, pinna, and possibly the mastoid area 
(May 2000, Eshraghi et al. 2002). Variable symptoms may accompany FP resulting 





 1. Nucleus nervus facialis 
 2. Nucleus salivatorius superior 
 3. Nervus intermedius (fibers to 
        lacrimal, salivary, and mucous 
        glands) 
 4. Nucleus tractus solitarii 
 5. Nervus intermedius (taste fibers) 
 6. Porus acusticus internus 
 7. Foramen acusticus internus 
 8. Ganglion geniculi 
 9. Nn. petrosus major and minor 
10. Second genu 
11. Nervus stapedius 
12. Chorda tympani 
13. Foramen stylomastoideum  
  
Figure 1. Course of the facial nerve from the brainstem through internal auditory and 
fallopian canals (labyrinthine, tympanic, and mastoid segments) to the stylomastoid 







Figure 2. A) Right-sided central facial palsy. B) Right-sided peripheral facial palsy. 
(Reprinted from Kanerva and Pitkäranta 2006 with permission of Duodecim Medical Journal.) 
 
 
Peripheral FP is associated with many diseases and phenomena; some causes are listed 
in Table 1.  
 
The history of documented peripheral FP stems from the ancient times of Egyptians, 
Greeks, Romans, Incas, and other native cultures with preserved art representing 
deformed faces with peripheral FP (Peitersen 2002). In the medical literature, Stalpart 
van der Wiel described in 1686 a woman with peripheral FP in the puerperium, 14 days 
postpartum (van de Graaf and Nicolai 2005). In addition, an unpublished description of 
acute peripheral FP without known cause by Douglas in 1704 and published 
documentation of three patients by Friedreich in 1797 are the first references to Bell’s 
palsy over 100 years and over 20 years before Bell’s studies (Peitersen 2002, van de 
Graaf and Nicolai 2005). Bell demonstrated that the facial nerve controlled facial 
motion and the trigeminal nerve facial sensibility (Bell 1821, 1829). The facial nerve 
became known as “Bell’s nerve”. For a while, all cases of peripheral flaccid paralysis 
were called “Bell’s palsy”, but later the term narrowed to only include idiopathic palsies 
without known cause. Bell mentions temporary diseases of the facial nerve in his work 
from 1829, but the concept of acute idiopathic peripheral paralysis was not contained in 
these early descriptions (Bell 1821, 1829).  
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 otitis media (acute and chronic) 
 herpes zoster 
 herpes simplex 
 exanthem subitum, human herpesvirus-6 or -7 













 penetrating wound 
 barotrauma 
Neoplasms  
 parotid gland 




Metabolic and toxic reasons 
 diabetes 
 hyper- and hypothyreosis 
 alcoholism 







Grading facial function 
 
A reliable way of grading is needed to define the severity of facial dysfunction, to 
follow the progression of FP, and to compare results of interventions. An internationally 
accepted and implemented system has not yet been developed. To assess correctly 
function and dysfunction of the facial nerve, the different aspects of its physiology need 
to be considered. The facial nerve innervates 23 paired facial muscles and the 
orbicularis oris, and the functional defect can vary in different parts of the face. In 
addition, lacrimation, salivation, and taste may be affected to varying degrees. When 
overall facial nerve function is assessed, an attempt to qualify and quantify these 
different types of function should be made. After facial nerve injury, secondary defects 
such as synkinesis, contracture, and hemifacial spasms may affect facial appearance and 
function variably and need to be considered in the assessment.  
 
House (1983) reviewed the existing facial grading systems and divided them into three 
categories: gross, regional, and specific. The general scales are called gross because 
they consider overall facial function, including degree of paralysis, and secondary 
effects simultaneously. They are descriptive, meant to categorize patients in a simple 
and practical way and not to give specific details about a patient’s facial function. In a 
regional system, the assessor scores different areas of facial function independently. 
Regional scales can be weighted or unweighted. In a weighted regional scale, certain 
areas of the face are considered less important because they are less likely to have a 
good return of function or are cosmetically or functionally less relevant (e.g. forehead) 
(House 1983). Specific systems ask questions about specific areas of the face and 
address the presence or absence of associated symptoms and signs (House 1983, Chee 
and Nedzelski 2000).  
 
The first facial grading system was introduced by Botman and Jongkees (1955). It was a 
simple five-category scale to judge the degree of paralysis (0 = normal, IV = total 
paralysis). Contractures were the only secondary defects mentioned in the grading in 
total paralysis. House (1983) considered this inappropriate since, according to him, in 
total paralysis secondary defects cannot develop. Peitersen (2002) modified the system 
and used that scale in his studies (Table 2). After analyzing the pre-existing grading 
systems, House (1983) introduced his gross scale system with six categories. 
Brackmann and Barrs (1984) meanwhile published a measuring system for side 
differences in facial movements. In 1985, the Facial Nerve Disorders Committee of the 
American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) adopted a 
universal standard of grading facial function based on the works of House and 
Brackmann (1985) (Table 3). The original House scale was modified and Brackmann’s 
measuring scale was added to assist in placing patients in the proper group. Clinicians 
were encouraged to convert their existing grading system to the House-Brackmann 
facial grading system (H-B FGS) when reporting their results, and the use of the system 
was required for articles in Otolaryngology-Head and Neck Surgery, the official journal 







Table 2. Peitersen grading system. 
 
Grade Degree of palsy Description of palsy 
0 None Normal function 
I Slight Only visible when patient grimaces 
II Moderate Visible with small facial movements 
III Severe Function just visible 





Table 3. House-Brackmann facial grading system. 
 
Grade Description Characteristics 
I Normal Normal facial function in all areas 
II Mild 
dysfunction 
Gross:   Slight weakness noticeable on close inspection; may 
              have very slight synkinesis 
At rest:  Normal symmetry and tone 
Motion: Forehead: moderate to good function 
              Eye: complete closure with minimal effort 
              Mouth: slight asymmetry 
III Moderate 
dysfunction 
Gross:   Obvious but not disfiguring difference between two 
              sides; noticeable but not severe synkinesis, 
              contracture, and/or hemifacial spasm 
At rest:  Normal symmetry and tone 
Motion: Forehead: slight to moderate movement 
              Eye: complete closure with effort 




Gross:   Obvious weakness and/or disfiguring asymmetry 
At rest:  Normal symmetry and tone 
Motion: Forehead: none 
              Eye: incomplete closure 
              Mouth: asymmetric with maximum effort 
V Severe 
dysfunction 
Gross:   Only barely perceptible motion 
At rest:  Asymmetry 
Motion: Forehead: none 
              Eye: incomplete closure 






Although widely used in the United States and Europe, H-B FGS failed to reach 
worldwide acceptance. Originally created as a gross scale, it has been criticized as not 
being sufficiently sensitive to document clinically significant changes (Murty et al. 
1994, Ross et al. 1996, Rickenmann et al. 1997). It is also prone to interobserver 
variation (Croxson et al. 1990, King et al. 1993, Murty et al. 1994, Ahrens et al. 1999, 
Coulson et al. 2005), and assigning only one grade may be difficult because of the 
different degrees of dysfunction in upper and lower parts of the face (Rickenmann et al. 
1997, Scriba et al. 1999, Yen et al. 2003). The article by House and Brackmann (1985) 
describing the grading system has become the most cited article in otolaryngology-head 
and neck surgery literature (Wormald et al. 2007). Demands for validation, reliability, 
and reproducibility assessments of the H-B FGS and its “golden standard” status have 
been made (Browning 2007). In Japan, the Yanagihara grading system is generally used 
(Satoh et al. 2000, Ikeda et al. 2003). It is an unweighted regional scale that assesses ten 
areas of the face without taking secondary effects into account (Table 4). Tables have 
been provided to convert Yanagihara scores to H-B FGS scores (Satoh et al. 2000).  
 
 
Table 4. Yanagihara grading system. 
 
 Normal Partial palsy/weak No motion 
 1 At rest 4 2 0 
 2 Wrinkle forehead 4 2 0 
 3 Close eyes normally 4 2 0 
 4 Close eyes forcefully 4 2 0 
 5 Close eyes on the involved side only 4 2 0 
 6 Wrinkle nose 4 2 0 
 7 Blow out cheeks 4 2 0 
 8 Whistle 4 2 0 
 9 Grin 4 2 0 
10 Depress lower lip 4 2 0 
 
 
Recently, the Sunnybrook (Toronto) Facial Grading System (SFGS) (referred to also 
simply as the Facial Grading System) (Ross et al. 1996, Ross and Nedzelski 1998, Hu et 
al. 2001) has received good reviews (Ahrens et al. 1999, Kayhan et al. 2000, Schaitkin 
and May 2000, Coulson et al. 2004, 2005) and is considered as a leading instrument in 
clinical use (Rogers et al. 2007). It is a regional scale that measures also synkinesis 
regionally (Table 5). The regional scores are weighted for the composite score. Berg et 
al. (2004) considered the scale promising and suggested adding objective measurements 
and secondary effects other than synkinesis to the scale to make it even better. 
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Table 5. Sunnybrook facial grading system (modified from Ross et al. 1996). 
 
Resting Symmetry 
Compared to normal side 
Symmetry of Voluntary Movement 
Degree of muscle excursion compared to normal side 
Synkinesis 
Rate the degree of involuntary 
muscle contraction associated 
with each expression 
Eye (choose one only) 
   normal                        0 
   narrow                        1 
   wide                            1 
   eyelid surgery             1 
Cheek (naso-labial fold) 
   normal                        0 
   absent                         2 
   less pronounced         1 
   more pronounced       1 
Mouth 
   normal                        0 
   corner drooped           1 
   corner pulled up/out   1 
 
 
                      Total_____ 
Resting symmetry score: 














Unable to   Initiates      Initiates               Movement   Movement 
initiate        slight          movement with   almost          complete 
movement  movement  mild excursion    complete 
       1                2                     3                     4                   5 
 
 
       1                2                     3                     4                   5 
 
 
       1                2                     3                     4                   5 
 
       1                2                     3                     4                   5 
 
       1                2                     3                     4                   5 
Gross            Severe         Moderate          Mild              Normal    
asymmetry   asymmetry   asymmetry       asymmetry    symmetry 
 
                                                                                   Total_____ 
                                Voluntary movement score: Total  4_____  
None* Mild† Moderate‡ Severe§ 
 
 
0            1            2             3    
 
 
0            1            2             3    
 
 
0            1            2             3    
 
0            1            2             3    
 





Synkinesis score: Total_____  
 
Voluntary movement score – (minus) Resting symmetry score – (minus) Synkinesis score = Composite Score_____ 
 
*no synkinesis or mass movement 
† slight synkinesis of one or more muscles 
‡obvious synkinesis of one or more muscles 
§disfiguring synkinesis/gross mass movement of several muscles 
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Impairment and disability experienced by the patient may differ greatly from the 
assessor’s grading (Bagger-Sjöbäck et al. 2005). Some investigators would include 
subjective assessment in the composite grading of facial function (de Ru et al. 2006), 
and others have created separate grading instruments for subjective dysfunction 
measurement (VanSwearingen and Brach 1996, Kahn et al. 2001, Mehta et al. 2007). 
 
All of the grading scales mentioned here and many others are subjective. One major 
problem with grading systems is finding a balance between exact descriptions of 
sequelae and minimizing the number of groups into which the patients are classified 
(Peitersen 2002). The need for an objective, simple-to-use method to measure facial 
dynamics is obvious, but it appears to be difficult to obtain. Significant differences exist 
in facial expressions from one individual to another, in sides of the face, and between 
genders and age groups (Giovanoli et al. 2003).  
 
Burres and Fisch (1986) introduced an objective method to measure distances between 
specific facial landmarks at rest and five standard expressions comparing the affected 
side of the face to the normal side (Burres-Fisch Linear Measurement Index) by using 
photographs and still video images. However, their method is time-consuming, difficult 
to use, and seems to underestimate the degree of dysfunction in severe paralysis and to 
overestimate it in mild paralysis (Croxson et al. 1990, Murty et al. 1994). Murty et al. 
(1994) simplified the system to the Nottingham System (Fig. 3, Table 6) by preserving 
objective measurements of three facial expressions (measuring the movements of four 
points on the face and comparing the abnormal side with the normal side as a 
percentage) and specifying whether secondary effects are present or absent and whether 
the patient experiences crocodile tears, dry eyes, or taste disturbances. The associated 
sequelae do not interfere with the measurement score and are not rated by severity. The 
system does not take into account possible normal variance in facial expression between 
the halves of the face (Chee and Nedzelski 2000) and is not applicable in bilateral FP 
because the affected side is compared with the unaffected side (Kang et al. 2002). Some 
investigators have found it promising, although more systemic evaluations are needed to 
determine whether a widespread application is appropriate (Kang et al. 2002). Others 
consider all linear measurements inadequate (Meier-Gallati et al. 1998). 
 
Many computer-aided analysis systems have been created to measure dysfunction of 
one part of the face (Tomat and Manktelow 2005), but to create a clinically usable and 
affordable method that takes into account whole-face function and secondary defects is 
challenging and still underway. Systems based on video-recording of facial expressions 
and light reflection (Neely et al. 1992, Yuen et al. 1997, Meier-Gallati et al. 1998) have 
been introduced, but because special equipment or techniques are required, these 
systems have not been taken into wide use (Chee and Nedzelski 2000). Automated 
facial image analysis (Cohn et al. 1999), originally created to detect, extract, and 
recognize emotion and paralinguistic expressions, has been used in clinical studies to 
distinguish subtle changes in facial movement after interventions (Rogers et al. 2007). 
The system requires manual marking of 40 points (with the computer mouse to video 
pictures), increasing the possibility for repeatability and agreement errors. Linstrom 
(2002) used a commercially available video-computer interactive system, The Peak 
Motus Motion Measurement System, to objectively measure the side-to-side 
displacement (asymmetry) of selected marker sites on the face during eye closure and 
smile, and concluded that the ideal objective system to both quantify and classify facial 
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motion remains to be found. Some investigators suggest that two-dimensional analyses 
might be inadequate and three-dimensional analyses would be more appropriate and 
accurate for detecting differences in facial function due to disfigurement or surgical 
interventions (Giovanoli et al. 2003). Some centers have three-dimensional systems in 
clinical use for pre- and postoperative asymmetry measurements in FP patients 
(Giovanoli et al. 2003). Computer-based systems to distinguish facial features and 
expressions are also used and developed in security systems and animation films, not 
only in medicine. Thus, numerous investigators work to solve this complex issue. An 
ideal facial grading system would be user-friendly, inexpensive, require minimal time 
and equipment, measure both static and dynamic components of facial function, be 
reliable, valid, and sensitive to changes over time or following treatments (Chee and 
Nedzelski 2000, Schaitkin and May 2000). Before such a method is available for 








SO = supraorbital 
IO = infraorbital 
LC = lateral canthus 
M = angle of mouth 
 
 
Figure 3. Facial reference points of the Nottingham grading system. 
 
 
Table 6. Nottingham grading system. 
 
Part 1: Calculations from reference points (Figure 3). 
 Right Left 
1. Raise eyebrows: measure distance SO–IO   
2. Close eyes tightly: measure distance SO–IO   
3. Smile: measure distance LC–M   
Sum =X =Y 
X/Yx100 = % 
 
Part 2: 
Hemifacial spasm Absent Present 
Contractures Absent Present 
Synkinesis Absent Present 
 
Part 3: 
Does your eye water when you eat? No Yes 
Is your eye drier than before? No Yes 
Have you noticed a change in taste? No Yes 
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Acute idiopathic peripheral facial palsy–Bell’s palsy 
 
In about 70% of adult peripheral FPs, the cause is unknown and the palsy is termed 
idiopathic (Bell’s palsy) (Adour et al. 1978, Peitersen 2002). Bell’s palsy is acute onset, 
usually reaching maximal intensity in a few days. The definition for the time limit 
within which the palsy has to reach its maximum to be Bell’s palsy varies from one to 
two weeks (Adour and Hetzler 1984) to up to three weeks (May and Hughes 1987). 
Criteria for Bell’s palsy have been unilateral FP without any other cranial neuropathies 
or neurologic deficits. The definition has been modified over the years with 
accumulating knowledge of the disease. Accompanying symptoms may arise from 
cranial nerves other than the facial nerve in acute peripheral FP without identifiable 
cause (Adour 2002, Benatar and Edlow 2004). Some investigators (Peitersen 2002) 
exclude patients with underlying conditions possibly predisposing to FP (e.g. diabetes 
or pregnancy) from the Bell’s palsy diagnosis, but in FP studies the cause of action is 
not uniform. Also spontaneous recovery to some degree within six months is considered 
a feature of Bell’s palsy by some investigators (May and Hughes 1987). In this thesis, 
Bell’s palsy is used as a synonym for acute idiopathic peripheral FP. 
 
Incidence of Bell’s palsy is about 20–30/100 000/year worldwide (Hauser et al. 1971, 
Adour et al. 1978, Katusic et al. 1986, Yanagihara 1988, Peitersen 2002, Rowlands et 
al. 2002, Ljøstad et al. 2005). In most studies, no racial, gender, or seasonal 
predisposition has been noted (Adour et al. 1978, Peitersen 2002, Rowlands et al. 2002). 
In some studies, people with diabetes or hypertension, and pregnant women are more 
susceptible to peripheral FP with worse outcome, but this is not seen in all studies 
(Gillman et al. 2002, Peitersen 2002). Age distribution of Bell’s palsy patients is 
variable. However, the consensus is that children under 15 years are less often affected 
than adults (Adour et al. 1978, Katusic et al. 1986, Peitersen 2002). Some studies report 
a rising frequency in patients over 60 years (Adour et al. 1978, Rowlands et al. 2002), 
whereas others describe the peak incidence age to be 15–45 years, with a reduced 
incidence in older people (Peitersen 2002). Recurrence of Bell’s palsy affects 6–13% of 
patients (Adour et al. 1978, Katusic et al. 1986, Devriese et al. 1990, Schaitkin et al. 
2000a, Peitersen 2002), and a positive family history varies between 1.5% (Katusic et 
al. 1986) and 17% (Schaitkin et al. 2000a). 
 
The etiology of Bell’s palsy is obscure; genetic, autoimmune, vascular, infective, and 
immunological causes have been speculated (McGovern et al. 1977, Fisch and Felix 
1983, Schaitkin et al. 2000c). Mechanisms include primary ischemia or inflammation of 
the facial nerve, causing edema and entrapment of the nerve in its long course in the 
bony temporal canal and resulting in compression and direct damage or secondary 
ischemia to the nerve (Fisch and Felix 1983, Schaitkin et al. 2000c). Another proposed 
mechanism is viral infection directly disturbing nerve function by inflammatory 
immune mechanisms, possibly throughout the nerve’s course and not by compression in 
the bony canal (Adour 2002). Herpesviruses have been suspected as etiologic factors for 
over 40 years, with growing evidence but still lacking the final proof (Dodge and 
Poskanzer 1962, McCormick 1972). The viral etiology has gained support by many 
associations of FP with viral diseases such as mononucleosis caused by Epstein-Barr 
virus (EBV), chickenpox caused by VZV, cytomegalovirus (CMV) infection, and case 
reports of exanthem subitum caused by HHV-6 or -7 (Traavik et al. 1983, Mori et al. 
2002, Pitkäranta et al. 2004). Some investigators consider Bell’s palsy to be a milder 
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version of Ramsay Hunt syndrome based on similar but less severe polyneuropathic 
symptoms, not necessarily caused by VZV (Adour 2002). Furuta et al. (2000, 2005) 
reported findings suggesting zoster sine herpete in about 30% of Bell’s palsy patients, in 
both adults and children, and considered VZV to be one of the major etiologic agents in 
Bell’s palsy. Their results were based on VZV DNA findings in saliva, VZV IgM 
findings in serum, or significant VZV IgG titer rise in paired serum tests. The 
conclusions can be challenged based on findings of VZV reactivation under nonsurgical 
stress (Mehta et al. 2004); VZV reactivation can be a consequence of the FP, not 
necessarily the cause. 
 
The strongest evidence for HSV-1 being the major etiologic factor in Bell’s palsy comes 
from the work of Murakami et al. (1996). Fourteen FP patients with ongoing palsies 
underwent decompression surgery 15–60 days after palsy onset (median 31 days). HSV-
1 DNA was found by polymerase chain reaction (PCR) in facial nerve endoneurial fluid 
from 10 patients (13 samples) and in tissue from the posterior auricular muscle from the 
seven previous patients and one additional patient (14 samples). DNA of VZV or EBV 
was not found. Nine Ramsay Hunt syndrome patients had the same procedures done, 
with seven positive VZV DNA findings in endoneurial fluid (9 samples) and six (one 
patient other than previous patients) positive muscle tissue findings (8 samples). DNA 
of HSV-1 or EBV was not found. Murakami et al. (1996) concluded that HSV-1 
infection of the facial nerve is directly related to the pathogenesis of Bell’s palsy, to 
reactivation of the virus in the geniculate ganglion. Many investigators agree and 
consider HSV-1 a plausible etiologic factor in Bell’s palsy (Furuta et al. 2001, Adour 
2002, Gilden 2004, Holland and Weiner 2004, Kawaguchi et al. 2007), some with 
supporting animal models (Honda et al. 2002). Others think caution in conclusions is 
warranted. HSV-1 and VZV are assumed to reactivate during surgical stress (Shea and 
Ge 2001), which could explain the findings of Murakami et al. (1996), or the viruses 
might reactivate because of FP. The PCR method used by Murakami et al. (1996) could 
not distinguish active from inactive infection. Stjernquist-Desatnik et al. (2006) took 
tissue samples from the posterior auricular muscle of Bell’s palsy patients within 72 
hours of palsy onset and found one patient with HSV-1 DNA by PCR. One Ramsay 
Hunt patient had VZV DNA in both a tissue sample and CSF. The authors discussed the 
discrepancy with findings of Murakami et al. (1996), speculating that epidemiological 
differences may exist in the countries of origin. They also noted that in the Murakami 
study the palsies were total and had lasted at least two weeks before samples were 
taken. Rowlands et al. (2002) did not find any suggestions of an infectious etiology: no 
household clustering of Bell’s palsy and no tendency of HSV infection preceding palsy. 
Linder et al. (2005) studied geniculate ganglions from 14 autopsy specimens of 
individuals without Bell’s palsy and found HSV-1 DNA in 86% and VZV DNA in 43% 
of ganglions. This confirmed previous abundant HSV and VZV DNA findings in 
cervical ganglia (Vrabec and Payne 2001). Linder et al. (2005) question the theory of 
HSV reactivation inside the geniculate ganglion as the reason for Bell’s palsy based on 
the discrepancy between the low incidence of Bell’s palsy and the frequent viral 
genomic findings in human geniculate ganglions. They conclude that the missing link to 
confirm the active role of HSV in Bell’s palsy is the identification of an active 





Human herpesvirus-6 and -7 
 
Studies on HHV-6 and -7 in FP patients are very few (details in Discussion). These 
viruses are usually acquired in childhood, persist latently for life, and reactivate 
occasionally (Ward 2005). Primary infections are either asymptomatic or accompanied 
by fever, diarrhea, rash, and roseola as the most usual symptoms (Zerr et al. 2005). So 
far, exanthem subitum is the only illness conclusively shown to be caused by HHV-6B 
or -7 (Yamanishi et al. 1988, Tanaka et al. 1994). Primary infections are sometimes 
accompanied by encephalitis or febrile seizures (Hall et al. 2006). The majority of 
documented primary infections are due to HHV-6B, and almost all children are HHV-6-
seropositive by two years of age (Ward 2005, Zerr et al. 2005, Hall et al. 2006). HHV-
6A has not been indisputably connected to any disease yet, and the epidemiology and 
clinical findings associated with acquisition of the virus remain uncertain. 
 
HHV-6 is the only human herpesvirus occasionally known to be integrated in human 
chromosomes. A consequence is the finding of high viral DNA copies in whole blood or 
serum samples; this is assumed to affect 0.7–1.5% of the general population (Tanaka-
Taya et al. 2004, Ward et al. 2007). No evidence of chromosomal viral integration of 
HHV-7 exists (Ward et al. 2007).  
 
Epidemiological characteristics and manifestations of acute HHV-7 infections are not 
well known. Primary HHV-7 infection usually occurs later than HHV-6 infection and is 
acquired over the first 5 or 6 years of life (Ward 2005, Hall et al. 2006). This is 
unexplained since contact with HHV-7 during infancy is expected to be at least as 
frequent as with HHV-6. Saliva of infected individuals is the presumed principal source 
of infection for infants. Both HHV-6 and -7 are shed in saliva (Ward 2005, Hall et al. 
2006).  
 
Like all herpesviruses, HHV-6 and -7 persist for life after primary infection and are 
detectable in peripheral white blood cells and multiple tissues (Ward 2005). In a study 
of autopsy samples, HHV-6 DNA was most commonly found in salivary glands, 
thyroid, stomach, intestines, liver, and pancreas, and HHV-7 DNA predominated in 
salivary glands, tonsils, lymph nodes, and bone marrow (Chen and Hudnall 2006). 
HHV-6 DNA has also been detected in the bone marrow of healthy individuals 
(Gautheret-Dejean et al. 2000) and both HHV-6 and -7 DNA in normal brain tissue at 
autopsy (Chan et al. 2000, Chan et al. 2001).  
 
The most serious clinical manifestations of infection or reactivation of these viruses 
occur in immunocompromised patients (Ljungman 2002). Some uncertainty remains 
about the clinical role of HHV-6 and -7 following organ or bone marrow transplantation 
(Ljungman 2002, Lehto et al. 2007). HHV-6 and -7 have been suggested to be 
associated with such conditions as multiple sclerosis, chronic fatigue syndrome, a 
variety of neoplastic disorders, infectious mononucleosis, meningitis, encephalitis, and 
drug hypersensitivity syndromes, and HHV-7 with pityriasis rosea (Ward 2005). 






Treatment of Bell’s palsy 
 
Bell’s palsy has been treated with various methods and medicines during its long 
history. Evaluation of therapy in Bell’s palsy is difficult because of the high 
spontaneous recovery rate. In many studies, treatment suggestions are based on the 
opinions of investigators rather than on results (Devriese et al. 1990, Austin et al. 1993). 
No consensus has been reached on the treatment of acute Bell’s palsy, but unanimous 
agreement exists on the importance of taking care of the affected eye, to protect it and 






 centuries, the etiology of acute peripheral FP was considered 
rheumatic, with the nerves hollow and filled by mucous fluid after being exposed to 
cold, and treatments were antirheumatic ointments and medicines (Peitersen 2002, van 
de Graaf and Nicolai 2005). Electrotherapy emerged in the 19
th
 century and is still 
controversial along with other physical therapy methods and acupuncture (Peitersen 
2002, van de Graaf and Nicolai 2005, He et al. 2007, Teixeira et al. 2007).  
 
Surgery for facial reanimation had already started at the end of the 19
th
 century, with 
anastomosing of the facial nerve to the accessory nerve and later to other neighboring 
nerves (e.g. hypoglossal, glossopharyngeal) (Ballance et al. 1903, Ballance and Duel 
1932). Decompression surgery of the facial nerve had been carried out in other 
indications and was introduced for Bell’s palsy in 1932 (Ballance and Duel 1932). 
Surgery became popular as the pathophysiology of Bell’s palsy was considered the 
entrapment and compression of the nerve in its bony temporal canal (Kettel 1947, Fisch 
and Esslen 1972). With the development of surgical methods and the assumed peak 
entrapment place of the facial nerve within the bony pathway, the area decompressed 
varied from the most distal part at the stylomastoid foramen to total decompression of 
the bony canal to the meatal foramen of the internal auditory canal (Fig. 1) (Ballance 
and Duel 1932, Fisch and Esslen 1972, Gantz et al. 1999, Yanagihara et al. 2001, Adour 
2002). The wait for an operation varied from a few days (Fisch and Esslen 1972) to 
several months (Kettel 1947, Yanagihara et al. 2001) or years (Kettel 1947). Besides the 
clinical picture of total paralysis or persistent palsy with sequelae, decisions for 
decompression surgery were based on various electrical tests (Ballance and Duel 1932, 
Kettel 1947, Gantz et al. 1999, Yanagihara et al. 2001, Adour 2002). With the 
herpesviral etiology gaining support, surgical procedures have declined and attitudes 
towards decompression surgery are controversial (Grogan and Gronseth 2001), with 
many investigators opposing the procedure (May et al. 1985, Adour 2002).  
 
Corticosteroids, cortisone initially, have been used in Bell’s palsy from the 1950s 
onwards to reduce inflammation, degeneration, and false regeneration of the facial 
nerve (Taverner 1954). The use is common around the world without a generally 
accepted scientific proof of effectiveness. The American Academy of Neurology 
(Grogan and Gronseth 2001) concluded in their practice guideline meta-analysis that 
while the benefit of steroids has not been established, they probably are effective in 
improving facial functional outcomes. They called for well-designed studies to 
investigate the effectiveness of treatments. Several other meta-analyses have supported 
the use of corticosteroids (Ramsey et al. 2000, Holland and Weiner 2004). The 
Cochrane database concludes the following: “The available evidence from randomised 
controlled trials does not show significant benefit from treating Bell's palsy with 
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corticosteroids. More randomised controlled trials with a greater number of patients are 
needed to determine reliably whether there is real benefit (or harm) from the use of 
corticosteroid therapy in patients with Bell's palsy” (Salinas et al. 2007). 
 
With the growing support for herpesvirus etiology in Bell’s palsy, the use of antiviral 
agents, first acyclovir, later valaciclovir and famciclovir, has emerged. The same is true 
as for corticosteroids; the results of studies are controversial, even within participants of 
the same collaborative study, as recently reported from Japan (Hato et al. 2007, 
Kawaguchi et al. 2007). The American Academy of Neurology (Grogan and Gronseth 
2001) stated that acyclovir (combined with prednisolone) may be effective in improving 
facial functional outcomes. The Cochrane database concludes: “More data are needed 
from a large multicentre randomised controlled and blinded study with at least 12 
months' follow-up before a definitive recommendation can be made regarding the effect 
of aciclovir or valaciclovir on Bell's palsy” (Allen and Dunn 2007). 
 
In 2001, a collaboration study was initiated in Finland and Sweden to assess the 
effectiveness of prednisolone and valaciclovir in Bell’s palsy (www.clinicaltrials.gov). 
This is a double-blind, placebo-controlled, randomized four-arm study with 739 
recruited patients and a one-year follow-up. Evidence for the benefit or ineffectiveness 
of these drugs in Bell’s palsy will hopefully be achieved. A similar recent study from 
Scotland (Sullivan et al. 2007) with 496 patients and 3- to 9-month follow-up 
demonstrated a significant benefit from the use of prednisolone compared with placebo, 
whereas the use of acyclovir alone or in combination with prednisolone was not 
effective. 
 
Corrective treatments for FP patients with residual palsy and associated sequelae 
include abundant reanimation surgical procedures to improve facial appearance and 
function, producing more balanced and symmetrical features (May et al. 2000a, 
Hadlock et al. 2006). After a spontaneous recovery period and especially after surgical 
corrections, physical therapy with various methods (muscle exercise, electrical 
stimulations, neuromuscular re-education therapies with surface electromyography 
biofeedback) is, albeit controversial, increasingly recognized and accepted as enhancing 
function and reducing discomfort and synkinesis (May et al. 2000, Targan et al. 2000, 
Beurskens et al. 2006, Hadlock et al. 2006, Teixeira et al. 2007). The mechanisms are 
thought to be CNS plasticity, resulting in better motor control of the facial muscles, and 
perhaps reinnervations from intact neighboring nerves or intact motor units of the facial 
nerve (Targan et al. 2000). Botulinum toxin is successfully used to diminish 
consequences caused by facial synkinesis, hemifacial spasms, hypercontracted muscles, 




Prognosis of Bell’s palsy 
 
Most Bell’s palsy patients recover well. Total recovery is seen in 70–80% of patients 
overall. With incomplete palsy, the recovery rate is 95–99%, with complete palsy 50–
60% (Katusic et al. 1986, Schaitkin et al. 2000c, Peitersen 2002). Roughly 30% of all 
patients are left with some sequelae (remaining palsy, hemifacial spasms, contracture, or 
synkinesis), mainly mild or moderate, but severe in 5% of cases (Devriese et al. 1990, 
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Peitersen 2002). In a Danish prospective 25-year study (Peitersen 2002), 70% of palsies 
were complete and 30% incomplete. Recovery began within three weeks for 85% and 
within 3–5 months for the remaining 15%. All Bell’s palsy patients achieved some 
degree of muscular function, as was evident also in a study by Adour et al. (1978). In 
the Danish study (Peitersen 2002), if recovery was not total within six months, some 
sequelae tended to remain in the final assessment. Total recovery was seen in 71% of 
Bell’s palsy patients, in 64% within three months (Peitersen 2002). Factors indicating 
unsatisfactory outcome are complete palsy, late beginning of recovery, and age over 60 
years (Katusic et al. 1986, Devriese et al. 1990, Schaitkin et al. 2000c, Peitersen 2002).  
 
There are no reliable signs or tests at palsy onset to predict outcome. Topognostic tests 
are unreliable because of anatomic variations, neural branching, and possible variations 
in the areas and components affected on the facial nerve (Karikoski 1987, Schaitkin et 
al. 2000b). Of the electrical tests used in prognostic evaluation, electroneuronography 
(ENoG), also called evoked electromyography, has been regarded as the most valuable 
in the acute phase of FP (Fisch 1984, Schaitkin et al. 2000b). A difference of 90% or 
more in the peak-to-peak amplitude of the evoked compound muscle action potential 
between the paretic and uninvolved sides of the face is considered to predict a 50% or 
greater chance of poor recovery (H-B FGS III or worse, Table 3) (Fisch 1984, Karikoski 
1987, Gantz et al. 1999). The major drawback of ENoG is that the site of testing is 
peripheral to the stylomastoid foramen and it takes a minimum of 72 hours for 
denervation to reach the distal parts of the nerve to be detectable (Schaitkin et al. 2000b, 
Chow et al. 2002). Since the beginning of palsy is considered crucial in the attempt to 
diminish the amount of denervation, the results of ENoG come late in finding patients at 
risk of poor outcome. Other limitations include marked normal variation within tests of 
the sides of the face and test to retest results (Sittel et al. 1998). Patient cooperation is 
mandatory and variations in electrode and stimulator placement and pressure can alter 
results (Schaitkin et al. 2000b, Chow et al. 2002). Studies on transcranial magnetic 
stimulation of the labyrinthine segment of the facial nerve have been conducted to 
evaluate the function of the nerve without the delay of distal testing (Schaitkin et al. 
2000b, Nowak et al. 2005), but this method has not reached clinical significance. 
Magnetic resonance imaging has its place in differential diagnostics of Bell’s palsy, but 
studies on predictive value of contrast enhancement findings in Bell’s palsy are 




Peripheral facial palsy in children 
 
In Peitersen’s Danish study (Peitersen 2002), neonates formed the largest group of 
children’s palsies (congenital and acquired). If neonatal age is excluded, Bell’s palsy 
comprised 77% of cases, which is in accordance with other studies (Ogita et al. 2006). 
Some studies have revealed the proportion of Bell’s palsy to be lower, 26–40% (Cook et 
al. 1997, Peltomaa et al. 1998, May et al. 2000b). In Peitersen’s study (2002), the 
overall incidence of peripheral FP in children under 15 years (excluding neonates) is 
3.4/100 000/year and of Bell’s palsy 2.6/100 000/year. Higher incidences have also 
been reported: for peripheral FP 21/100 000/year (under 14 years) (Tveitnes et al. 2007) 
and 7/100 000/year (Christen et al. 1993), and for Bell’s palsy 5–8/100 000/year (Adour 
et al. 1978, Katusic et al. 1986). Many studies conclude prognosis of FP in children to 
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be excellent; 90% recovered completely in Peitersen’s study (2002), but full recovery 
rates of 70–80% are also common (Peltomaa et al. 1998, Skogman et al. 2003). 
 
In adult populations, borreliosis as a causative agent for peripheral FP accounts for 0–
20% of cases (Roberg et al. 1991, Peitersen 2002, Ljøstad et al. 2005) mostly 
manifesting with additional symptoms besides FP (Ljøstad et al. 2005). In studies from 
endemic areas, borreliosis explains 30–65% of children’s FPs (Christen et al. 1993, 
Peltomaa et al. 1998, Tveitnes et al. 2007). Many of these children have no other 
neurological signs besides FP (Christen et al. 1993, Tveitnes et al. 2007). The Danish 
study (Peitersen 2002) did not have any children with diagnosed borreliosis. The same 
was true with 30 children in Japan (Furuta et al. 2005); instead VZV was suspected as 
the causative agent in 30% of cases. False-positive findings of IgM antibodies to 
Borrelia burgdorferi in CSF can be caused by VZV or EBV, and it is important to rule 
out these infections before confirming borreliosis as the causative factor for FP 




Melkersson-Rosenthal syndrome  
 
In 1928, Swedish neurologist Ernst Melkersson published a case study of a 35-year-old 
man whose FP had reoccurred four times and who had had attacks of edema in the 
upper and lower lip since age 14 (Melkersson 1928). The swelling in the lower lip 
gradually became persistent. In 1931, a German neurologist Curt Rosenthal published a 
family study in which four women from three unrelated families had at least one 
episode of FP, recurrent episodes of edema, and LP (Rosenthal 1931). Two of these four 
women were sisters and their mother had had reoccurring facial edema. The third 
woman had a sister with FP and LP, and a mother with LP. The fourth woman was the 
only one in her family with these symptoms. In one additional family, edema and LP 
were seen in two generations without FP (Rosenthal 1931). Recurrent labial or oro-
facial edema, recurrent FP, and associated LP (also referred as fissured or furrowed 
tongue) occurring without recognizable cause became known as the classical triad of 
MRS. Swiss dermatologist Alfred Guido Miescher studied histology of reoccurring 
labial edema and found peri- and paravascular tuberculoid character granulations in 
edematous tissue samples (Miescher 1945). He regarded the finding as cheilitis 
granulomatosa (CG). Later, German dermatologists (Richter and Johne 1950, Gahlen 
and Brückner 1951) made similar findings in edematous tissue samples from MRS 
patients: nonnecrotizing (-caseating) lymphoepiteloid granulomas. Miescher’s CG has 
since been considered by many investigators as a monosymptomatic form of MRS 
(Hornstein 1973, Worsaae et al. 1982, Greene and Rogers 1989). When two of the 
possible three symptoms are present, the form is called oligosymptomatic MRS (Greene 
and Rogers 1989, Hornstein 1997). Some investigators demand that edema be one of the 
two symptoms for the diagnosis of MRS (Mair and de Graaf 1974), most, however, also 
include patients with FP and LP without edema (Ekbom 1950, Greene and Rogers 1989, 
Hornstein 1997). Some investigators still question the supposed mutual etiology of 
monosymptomatic form of MRS with oligosymptomatic or triad form of MRS, because 
most CG patients never develop other symptoms of MRS (van der Waal et al. 2002). 
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Edema is considered the most frequent and dominating clinical feature in MRS 
eventually affecting virtually all patients (Hornstein et al. 1987, Greene and Rogers 
1989). The upper lip (skin and mucosa) is the most common site, but any oro-facial area 
(outer or inner sides of cheeks, eyelids, forehead, nose, gingiva, oral cavity, floor of 
mouth, tongue, pharynx, and larynx) may be involved (Zimmer et al. 1992, Hornstein 
1997). Extrafacial edemas have been described in the chest, dorsum of hands and feet, 
buttocks, and genitals (Hornstein 1973, Tsuboi et al. 2005). The edema is nonpitting, 
painless, and thought to eventually become persistent (Greene and Rogers 1989). The 
triad form of MRS is estimated to occur in up to 20% of all cases and FP in 20–50% 
(Vistnes and Kernahan 1971, Hornstein 1973, Worsaae et al. 1982, Hornstein et al. 
1987, Greene and Rogers 1989, van der Waal et al. 2002). LP is found in about 6% of 
the general population, with an increasing prevalence with age (children 0.5%–elderly 
people 15%) (Axell 1976). LP is considered the least important clinical feature of MRS 
and is found in about 50% of patients (Rintala et al. 1973, Worsaae et al. 1982, Greene 
and Rogers 1989). Most MRS studies, usually from departments of dermatology or oral 
or plastic surgery, have many CG patients and patients with FP are the minority 
(Worsaae et al. 1982, Hornstein et al. 1987, van der Waal et al. 2002). 
 
Besides the triad of classical symptoms, additional symptoms frequently accompany 
MRS. Hornstein (1997) considers palsies or dysfunctions of other cranial nerves besides 
the facial nerve to be “major signs” of MRS in addition to edema and FP. In the 
complete form of MRS, Hornstein (1997) emphasizes recurrent facial edemas and 
histopathological findings of nonnecrotizing granulomatous infiltarations in edematous 
tissue samples. He also lists numerous “minor signs” of uni- or bilateral sensory, motor 
neuron, or autonomous disturbances that can accompany MRS and support the 
diagnosis of MRS in oligosymptomatic forms. These include facial dysesthesia, 
headaches, tinnitus, relapsing hearing loss, dizziness, recurrent pharyngeal neuralgias 
and spasms, dysphagia, recurrent dysfunctions of salivary and tear secretion, excessive 
facial sweating or anhidrosis, and recurrent dry eye or dry mouth sensations. When FP 
and LP are the presenting symptoms without edema, Hornstein (1997) demands the 
presence of two or more minor signs for a diagnosis of MRS. Hornstein et al. (1987) 
found migraine in 41% of MRS patients. 
 
The etiology of MRS is unknown. Family occurrence has been documented starting 
with Rosenthal in the 1930s (Rosenthal 1931, Carr 1966, Lygidakis et al. 1979, 
Levenson et al. 1984). Whether the familiar pattern is a result of a genetic 
predisposition, immunodeficiency, or transmission of an infectious agent remains to be 
elucidated (Levenson et al. 1984). To exclude a pure infectious origin, Meisel-Stosiek et 
al. (1990) examined spouses of MRS patients alongside family members. They found an 
increased risk for MRS of 24% in first-degree relatives of MRS patients. The risk 
dropped to 5% in second-degree relatives. Based on their study and a review of previous 
reports on family occurrence of MRS, they concluded that MRS is most likely 
multifactorial in origin, with a hereditary component. Besides heredity, a disturbed 
autonomous nervous or immune system, obstructive microcirculation, allergies, 
sarcoidosis, Crohn’s disease, inflammatory agents (toxoplasmosis, tuberculosis, viral 
infection) have been suggested as causative agents (Hornstein 1973, Greene and Rogers 
1989, Sussman et al. 1992, van der Waal et al. 2002). Hornstein (1997) speculated that 
one common causative denominator of the disease is very unlikely in view of the variety 
of clinical forms and accompanying symptoms in MRS patients. 
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The incidence of MRS remains obscure. Hornstein (1973) reported an incidence of 
80/100 000 (120 MRS patients in 18 years, most patients with monosymptomatic CG). 
About 25% of his MRS patients had FP, corresponding to an incidence of 20/100 000. It 
is not defined, whether the incidence is for a year or for all 18 years. For an annual 
incidence this seems high since the incidence of Bell’s palsy is the same: 20–30/100 
000/year worldwide (Devriese et al. 1990, Peitersen 2002). The Danish study (Peitersen 
2002) collecting information on FP etiology and incidence had 19 MRS patients (only 
the number given, no further information). This equals an incidence of 0.36/100 
000/year for MRS with FP and a total incidence of 0.7–1.8/100 000/year for MRS if FP 
is present in 20–50% of all cases.  
 
MRS has been found in children as well as in the elderly, but the most common age at 
onset is 25–40 years (Worsaae et al. 1982, Hornstein et al. 1987, Zimmer et al. 1992). 
Whether both genders are affected equally is difficult to determine due to the small 
number of patients: the female–male ratio has been reported to be 2:1 in some studies 
(Hornstein et al. 1987, Zimmer et al. 1992), but equal distribution or male 
predominance have also been described (Rintala et al. 1973, Worsaae et al. 1982).  
 
Treatment of MRS has been unsatisfactory. For edema, the most common treatment is 
corticosteroids: systemically, topically, or as intralesional injections, with inconsistent 
results (Worsaae et al. 1982, Zimmer et al. 1992, Hornstein 1997, van der Waal et al. 
2002, Mignogna et al. 2004). Allergy medications and antibiotics have mostly been 
ineffective (Worsaae et al. 1982, Zimmer et al. 1992). Medications used for 
tuberculosis, or autoimmune diseases, and skin and connective tissue diseases, such as 
dapsone, azathioprine, sulfasalazine, chloroquine, clofazimine, and tumor necrosis 
factor alpha inhibitors (thalidomide and infliximab), have been tried without definite 
results (Sussman et al. 1992, Zimmer et al. 1992, Hornstein 1997, Barry et al. 2005). 
Eradication of underlying odontogenic infections has proved successful in some patients 
with edema (Worsaae et al. 1982). Reduction cheiloplasty has produced some good 
results in permanent lip swellings with nonactive disease, but recurrence is common 
(Kruse-Lösler et al. 2005). For relapsing FP, total nerve decompression has been 
suggested (Dutt et al. 2000), but the limited number of patients treated and followed up 
and the varying natural cause of the disease make it difficult to draw conclusions. 
Whether the syndrome sometimes completely resolves is uncertain (Worsaae et al. 
1982). 
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AIMS OF THE STUDY 
 
 
The general aim of this study was to assess grading and etiology of peripheral FP and 
characteristics of MRS. 
 
Specific aims were as follows: 
 
1. To assess intrarater repeatability and interrater agreement of H-B FGS and SFGS. 
 
2. To evaluate the etiologic role of human herpesviruses in peripheral FP by searching 
for HSV-1 and -2, VZV, HHV-6A, -6B, and -7, EBV, and CMV DNA in CSF of FP 
patients. 
 
3. To investigate differences in MRS patient characteristics in the two specialty 
departments of Otorhinolaryngology and Dermatology, and special characteristics of 
MRS in patients with FP. 
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SUBJECTS AND METHODS 
 
 
All study protocols (I, II, III, IV) were approved by the ethics committee of Helsinki 







Eight patients with unilateral peripheral FP were video-recorded showing five standard 
facial expressions. One of the patients had FP after vestibular schwannoma operation 12 
years earlier and had had an eyelid operation. The other seven patients had Bell’s palsy, 
which had lasted one year in five patients, two months in one patient, and two weeks in 
one patient. Five patients had synkinesis and two had contracture. 
 
Thirty doctors at the Department of Otorhinolaryngology, Helsinki University Central 
Hospital, volunteered to be assessors of the videos. There were two assessment rounds 
and 28 doctors (15 residents and 13 specialists) returned their gradings for the first 
round and 26 (13 residents and 13 specialists) for both two rounds. 
 
Studies II and III  
The study group comprised 33 peripheral FP patients with 34 CSF samples. Of these 
patients, 26 had Bell’s palsy, 5 had simultaneous herpesvirus infection, one had MRS, 
and one had puerperal FP two weeks after delivery. These patients were selected 
because herpesviruses are suspected etiologic factors in Bell’s palsy and in FP cases 
with concomitant herpesvirus infection, and an association may also exist in MRS. 
Puerperal FP is not considered Bell’s palsy by some investigators, whereas others 
include it in the definition.  
 
There were 19 females and 14 males. Their median age was 19 (range 4–78) years, and 
16 patients were 15 years or younger (median 13 years). The median time for the CSF 
sample to be taken after palsy onset was 21 days (range 0–148, 0 being the day palsy 
started). One of the patients had three episodes of Bell’s palsy and her CSF sample was 
taken twice. Three other patients had a second occurrence of Bell’s palsy. For the MRS 
patient, this was her fourth FP episode. Among the five patients with concurrent 
herpesvirus infection, one had bilateral FP and EBV infection, two had 
varicella/chickenpox preceding FP, one had Ramsay Hunt syndrome with blisters in her 
mouth a week before FP, and one had simultaneous eruption of herpes blisters on her 
lower lip on the palsy-affected side.  
 
The 36 control subjects were unmatched and their CSF samples were taken during the 
same time interval as those of the study group. Six controls had FP with borreliosis. 
Possible borreliosis with elevated serum antibodies to Borrelia burgdorferi but normal 
CSF samples was evident in 13 control subjects: nine with FP, two with sudden 
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deafness, one with hearing loss and tinnitus, and one with vertigo. No borreliosis was 
suspected in the remaining control subjects. Four had sudden deafness, five had vertigo, 
and four had headache and arthralgia. Of the last four controls, one had headache, one 
had vocal cord paralysis, one had facial erysipelas with sepsis and simultaneous 
cavernous sinus thrombosis and peripheral FP, and one had ear symptoms, atypical 
papillitis, headache, and vertigo. The control group comprised 19 females and 17 males. 
Their median age was 47.5 (range 5–75) years, with three controls being 15 years or 
younger. 
 
No diabetic or immunocompromised patients or controls were included in the study. 
 
Study IV 
There were 35 patients with MRS or suspicion of the syndrome: 23 females and 12 
males. Median age at study onset was 47 (range 19–75) years. Median age at symptom 
onset was 24 (range 5–71) years. Twenty of the 35 patients had history of FP: 13 
females and 7 males. Median age for MRS FP patients was 45.5 (range 34–74) years 
when the study started and 21.5 (range 10–67) years at symptom onset. The remaining 
15 patients, 10 females and 5 males, had CG, monosymptomatic MRS. Their median 








Video-recording of the FP patient was started with the face at rest, followed by five 
standard facial expressions: lifting the eyebrows/wrinkling the forehead, closing eyes 
gently and then more powerfully, wrinkling the nose, smiling mouth open, and 
puckering the lips. Each movement was repeated three times. After doing all five 
expressions three times each, the patient again repeated each three times. By doing this, 
we tried to minimize the need to pause the videotape while assessing. 
 
Doctors graded the facial appearance and movements from the videotapes by H-B FGS 
and SFGS. Before the first-round videos were delivered to the assessors, a session with 
an opportunity to view an SFGS teaching video was held. A brief memo highlighting 
both grading scales and synkinesis accompanied the grading booklet together with 
patient information on FP duration and palsy side. Assessments by doctors were done 
twice, with a three-week interval. For the second round, the order of the patients in the 
video was changed from the first round. The grading was done anonymously and 
privately, independently from the other assessors.  
 
Study II 
PCRs for HSV-1, VZV, and HHV-6 were performed as described in detail by Pitkäranta 
et al. (2000). Briefly, DNA was isolated from CSF by proteinase K digestion, followed 
by phenol extraction and ethanol precipitation. Ten microliters of the template was 
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added to the PCR reaction representing 100 µl of the CSF sample. The primers used in 
PCR reactions were chosen from the polymerase genes for HSV-1 according to 
Piiparinen and Vaheri (1991) (5´-biotin-AAGGAGGCGCCCAAGCGTCCG-3´ and 5´-
TGGGGTACAGGCTGGCAAAGT-3´) and for VZV according to Echevarria et al. 
(1994) (5´-AGGTACC GAAAAGCGT-3´ and 5´-biotin-GGCATGTCCCGATGTGGA 
AA-3´), and from the U67 gene for HHV-6 according to Gopal et al. (1990) (5´-
AAGCTTGCACAATGCCAAAAAAC G-3´ and 5´-biotin-CTCGAGTATGCCGAGA 
CCCCTAATC-3´). Positive and negative controls were included in each run. The 
amplified products were detected by microplate hybridization. Hybridization was 
carried out as described previously by Vesanen et al. (1996) and Pitkäranta et al. (2000). 
Specific oligonucleotide probes were used (5´-CCC TCC TCG CGT TCG TCC TCG-3´ 
for HSV-1, 5´-ATA ACT CGC TAC CGG AAC GTA TGC CAC AAG-3´ for VZV, 5´-
AAC TGT CTG ACT GGC AAA AAC TTT T-3´ for HHV-6) to demonstrate different 
amplified products.  
 
Study III 
The controls of the multiplex-PCRs and microarrays were viral DNA of HSV-1 strain 
MacIntyre, HSV-2 strain G, CMV strain AD169, EBV strain B95-8, HHV-7 strain H7-
4, HHV-6A strain U1102, HHV-6B strain Z-29, and VZV Rod strain (Autogen 
Bioclear, Wiltshire, UK).  
 
DNA was extracted using a High Pure Viral Nucleic Acid Extraction Kit (Roche 
Diagnostics, Basel, Switzerland). The CSF (200 µl) was extracted and eluted to 50 µl of 
elution buffer. Two multiplex-PCRs were used for amplification of herpesvirus 
genomes, as described in detail by Jääskeläinen et al. (2006). Multiplex-PCR1 (5 µl of 
extraction) was used to identify HSV-1 and -2. Multiplex-PCR2 (10 µl of extraction) 
contained primer pairs for amplification of CMV, EBV, VZV, HHV-6A, -6B, and -7. 
Both multiplex-PCRs were carried out for each sample. The T3 RNA polymerase 
promoter sequence (AATTAACCCTCACTAAAGGGAGA) was included in the 
reverse primers of the multiplex-PCRs. The oligonucleotides, oligonucleotide positions, 
GenBank accession numbers, and gene names are provided in the Appendix. 
 
Microarrays were prepared at the National Public Health Institute (Finland), as 
described by Jääskeläinen et al. (2006) with a minor modification. Instead of spotting 
solution containing 0.3 M sodium carbonate buffer (pH 9), the commercial 1  
microarray spotting solution (ArrayIt, Telechem International, Sunnyvale, CA, USA) 
was used. The array consisted of a 5  12 matrix that included 14 oligonucleotides 
(Proligo, Paris, France); 8 were specific and 6 unspecific for herpesviruses. Microarrays 
contained 44 subarrays, and the herpesvirus-specific oligonucleotides were spotted in 
2  triplicate and unspecific oligonucleotides twice per subarray. The spotting was 
performed at room temperature and 50% humidity. Microarrays were stored overnight 
at room temperature before use.  
 
First, two multiplex-PCR products of each sample were pooled, and the product 
solution was transcribed into single-stranded RNA using a AmpliScribe™ T3 High 
Yield Transcription Kit (Epicentre, Madison, WI, USA) following the manufacturer’s 
instructions. Second, the hybridization of single-stranded RNA to specific 
oligonucleotides on microarrays was performed. Finally, primer extension reactions 
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were performed, and microarrays were washed with array washing buffer and dried 
before scanning (Jääskeläinen et al. 2006).  
 
The microarrays were analyzed using a ScanArray Express scanner (PerkinElmer, 
Wellesley, MA, USA). Images were generated with the ScanArray
TM
 software and 
quantified using the QuantArray
TM
 software provided by PerkinElmer. A cut-off value 
was determined for each array separately using QuantArray
TM
 software and signals of 
unspecific oligonucleotides and background (Jääskeläinen et al. 2006). Microarray 
detection and genotyping were carried out in duplicate for each sample. The detection 
limits of the microarray, using commercial viral DNA controls, were as follows: HSV-1 
9.1 virus particles (VPs), HSV-2 8.0 VPs, VZV 4.5 VPs, HHV-6A 7.0 copies, HHV-6B 




A computer search of patient records from January 1
st
, 1996 to June 30
th
, 2007 was done 
for MRS at the Departments of Otorhinolaryngology and Dermatology (Skin and 
Allergy Hospital), Helsinki University Central Hospital.  
 
LP was defined according to Axell (1976): the dorsum or margins of the tongue are 
crossed by one or several grooves estimated to be at least 2 mm deep over a minimum 
total length of 15 mm. If there was any question in patient charts about the LP, severity 
was considered moderate and not recorded as actual LP.  
 
All patient records were studied and a questionnaire was sent to patients with FP. They 
were asked about the time, side, and number of their FPs; about the location, duration, 
frequency, and persistence of facial edema; and about the existence of edemas in other 
body parts. We inquired whether any relatives had FP, edemas, or fissured tongue. 
Patients were also questioned about additional symptoms (IV, Table 1). They were 
asked about allergies, any other diseases, medications, or gastrointestinal symptoms. 
Finally they were requested to attend a clinical examination.  
 
If the patient had LP, the tongue was photographed. Facial function was determined by 
H-B FGS (Table 3) and SFGS (Table 5).  
 
A tissue sample from the edematous area (lip, cheek, tongue) was taken with a 4-mm 
biopsy punch (in cheek and lip edema from inside the mouth deep to the underlying 
muscle) for possible granulomatous infiltration diagnosis. The samples were stored in 
formalin overnight. Paraffin-embedded samples were then cut and stained with 
hematoxylin-eosin and periodic acid-Schiff. The slides were examined by a 
dermatopathologist.  
 
A blood sample was drawn for genetic testing from 13 patients. The samples were 
stored at -20°C until further use. Genomic DNA was isolated using a QiaAmp DNA 
blood mini kit according to the manufacturer's instructions (Qiagen, Hilden, Germany). 
DNA was eluted into 100 µl of water. Mutation locations in chromosome 11q13 for 
gene UNC-93B1 were amplified in two independent reactions using 2.5 µl of extracted 
DNA. The specific primers used for 1034del4 were forward 5'-GGAGGGGGATATTT 
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GGGATA-3' and reverse 5'-CAAGTAATGGGTTCGCAGGT-3', and for 781G>A 
forward 5'-GGCTGGGTCAGATGTCCTAA-3' and reverse 5'-CCAGCTGCCCATGAT 
TTATT-3'. PCR was performed by using 2.5 units of AmpliTaq Gold polymerase 
enzyme (Applied Biosystems, Foster City, CA, USA), 1  buffer, 2 mM MgCl2, 0.25 
mM dNTP mix (Finnzymes, Espoo, Finland), 0.6 µM each of primers (purchased from 
Sigma-Proligo, Paris, France), and 5% DMSO. PCR-products were purified by 
QIAquick Gel Extraction Kit (Qiagen) and sequenced.  
 
Statistical analysis  
In Study I, statistical analyses were performed using SPSS for Windows, version 12.0 
(SPSS Inc., Chicago, IL, USA). 
Repeatability for SFGS was assessed by calculating coefficient of repeatability (CR) 
and intraclass correlation coefficient (ICC) with 95% confidence intervals (CIs) for each 
doctor and for the composite score and each component (resting symmetry, voluntary 
movement, and synkinesis) separately. The within-patient standard deviation (σe) was 
estimated from the standard deviation (SD) of the difference between the second- and 
first-round scores (S2-S1): σe = SD/√2. CR was then estimated as CR = 2.83  σe. The 
ICC values were interpreted as follows: <0.40 poor, 0.40–0.75 fair to good, and 0.75 
excellent repeatability (Fleiss 1986). 
To indicate the degree of repeatability for H-B FGS, exact agreement percentage and 
weighted kappa coefficients were calculated for each doctor (Altman 1991). In weighted 
kappa, different weights were assigned to disagreements since a discrepancy of one 
category was considered to indicate less disagreement than a discrepancy of two 
categories, and a discrepancy of three categories to indicate even more disagreement. 
The kappa values were interpreted as follows: <0.20 poor, 0.21–0.40 fair, 0.41–0.60 
moderate, 0.61–0.80 good, and 0.81–1.00 very good agreement (Altman 1991).  
Agreement between doctors for SFGS was assessed by calculating CR and ICC for the 
composite score and for each individual component. The first and second assessments 
were analyzed separately. The within-doctor SD (σe) was estimated by using the square 
root of the mean square error from one-way analysis of variance, with patient as the 
grouping factor (and doctor as the repeated factor). CR was then estimated as CR = 2.83 
 σe. For H-B FGS, agreement was estimated by calculating overall agreement 
percentage and generalized kappa coefficients. 
Student´s t-test was applied to compare repeatability and agreement estimates between 
the two observer groups.  
 






Study I  
 
Repeatability results (intrarater reliability) for composite score and the individual 
components of SFGS by CR are presented in Table 7. The mean composite score CR 
with observer groups combined was 16.97, indicating that with 95% probability 17 
points would be the upper limit of a score difference between two random assessments 
for one patient. CR results have to be interpreted case by case; no available standard 
exists. On a scale from 0 to 100, 17 points is a good outcome (1/6 of the scale range), 
although not excellent. The mean CR for repeatability of resting symmetry was 1.62 
points (~1/3 of scale range 0–4), a moderate or fair outcome; for voluntary movement 
3.13 (~1/7 of scale range 5–25), an excellent outcome; and for synkinesis 3.47 (~1/5 of 
scale range 0–15), a good outcome. No statistical difference was present between the 
two groups of assessors, residents and specialists in any of the measurements: 
composite score (t-test, P = 0.159), resting symmetry (P = 0.370), voluntary movement 
(P = 0.143), and synkinesis (P = 0.112). The mean ICC representing the repeatability 
for composite score and the individual components of SFGS varied from 0.819 to 0.983, 
meaning excellent repeatability. Differences between assessor groups again were not 
significant: composite score (t-test, P = 0.234), resting symmetry (P = 0.289), voluntary 
movement (P = 0.203), and synkinesis (P = 0.078). In conclusion, the SFGS composite 
score repeatability varied from good to excellent and the individual components 




Table 7. Repeatability results for Sunnybrook facial grading system composite score 
and individual components (scale range in parentheses) by coefficient of repeatability.  
 










































Total Mean 16.97 1.62 3.13 3.47 
 






To define repeatability for H-B FGS, the mean agreement percentage for identical 
assessments was 63% (Table 8). The difference between the two observer groups was 
not significant (P = 0.835). We consider this result fair. The weighted kappa coefficient 
was calculated for each doctor separately. Residents (n = 13) had a good weighted 
kappa in nine cases (69%) and a very good weighted kappa in four cases (31%). 
Specialists (n = 13) had a moderate weighted kappa in two cases (15%), a good 
weighted kappa in seven cases (54%), and a very good weighted kappa in four cases 
(31%). The mean weighted kappa for residents was 0.75 (good) and for specialists 0.71 
(good) (Table 8). The difference between the observer groups was not statistically 
significant (P = 0.349). In conclusion, H-B FGS repeatability varied from fair to good 
depending on the statistical method used. 
 
 
Table 8. Repeatability results for House-Brackmann facial grading system by 
percentage of identical assessments for each doctor (Agreement %) and weighted kappa 
coefficient.  
 



















Total Mean 63.0 0.73 
 
Residents (n=13) and specialists (n=13) graded eight patients twice. 
 
 
To assess agreement between doctors (interrater reliability) for SFGS, the composite 
score CR was 23.90 in the first round and 22.90 in the second round. The agreement 
between doctors was slightly but not significantly better in the second round. The mean 
of 23.40 is about 1/4 of the scale range of 0–100, a moderate result. The composite 
scores are presented in Fig. 4. The agreement result for resting symmetry by CR was 
1.88/1.94 (assessment round 1/round 2). The mean of 1.91 is more than 1/3 of the scale 
range of 0–4, a moderate or fair outcome. For voluntary movement, CR was 4.74/4.16; 
the mean of 4.45 is 1/5 of the scale range of 5–25, a good outcome. For synkinesis, CR 
was 5.32/4.96; the mean of 5.14 is approximately 1/3 of the scale range of 0–15, a 
moderate or fair outcome. The assessment round with a better outcome varied, but the 
results did not differ significantly. The ICC for the composite score was 0.997 (95% CI 
0.992–1.000) in the first round and 0.997 (95% CI 0.993–1.000) in the second round. 
The agreement results for SFGS components by ICC varied from 0.980 to 0.997. All 
ICC results indicated excellent agreement. In conclusion, SFGS agreement for 
composite score varied from moderate to excellent and the individual components 




Figure 4. Sunnybrook facial grading system (SFGS) composite scores for eight patients 
(Pat 1–8) assessed twice (I, II) by 26 doctors. The boxes indicate the lower and upper 
quartiles, and the central line is the median. The upper end of the bar is the maximum 
value, and the lower end the minimum value. Outliers are presented as open circles (o).  
(Reprinted with permission from Elsevier.) 
 
The distribution of H-B FGS grades in assessing agreement between doctors is shown in 
Table 9. The overall agreement percentage between doctors was 48% in the first round 
and 51% in the second round. We consider the mean overall agreement percentage of 
50% a poor outcome. The generalized kappa coefficient of 0.34 (95% CI 0.32–0.36) in 
the first round and 0.37 (95% CI 0.34–0.40) in the second round of assessment indicated 
only fair agreement among the 28 and 26 doctors, respectively. Agreement was slightly 
but not significantly better in the second round. In conclusion, H-B FGS agreement 
varied from poor to fair depending on the statistical method used. 
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Table 9. Distribution of House-Brackmann facial grading system (H-B FGS) grades  
(I–VI) for each of the eight patients by 28 assessors in the first assessment round and 26 




 assessment H-B FGS grades  2
nd
 assessment H-B FGS grades 
 I  II III IV  V VI Total I II III IV V VI Total 
1 1 18 9 0 0 0 28 0 12 14 0 0 0 26 
2 0 0 8 14 6 0 28 0 0 3 11 12 0 26 
3 23 5 0 0 0 0 28 23 3 0 0 0 0 26 
4 0 1 8 9 10 0 28 0 0 3 15 8 0 26 
5 0 0 6 19 3 0 28 0 0 2 18 6 0 26 
6 0 11 16 1 0 0 28 0 4 16 6 0 0 26 
7 0 0 4 8 16 0 28 0 0 0 8 17 1 26 
8 7 21 0 0 0 0 28 7 18 1 0 0 0 26 




Studies II and III  
 
Three patients and five controls revealed HHV-6 or -7 DNA in CSF (Table 10). HSV-1 
or -2, VZV, or CMV DNA was not detected in CSF of any patient or control. Of the 
positive patient findings, one HHV-6 DNA was in Study II from a 58-year-old man who 
had FP with arthralgia (Table 10, patient 1). He had suffered poliomyelitis and 
tuberculosis as a child and his CSF albumin ratio and protein levels were slightly 
elevated. The CSF sample was taken 45 days from FP onset. The patient recovered 
totally in six months. In Study II, distinction between HHV-6 variants A and B was not 
possible. In Study III, a 13-year-old girl (Table 10, patient 2) with FP and no additional 
symptoms had HHV-7 DNA, and a woman (Table 10, patient 3) who had given birth 
two weeks prior to FP onset had simultaneous findings of HHV-6A and -6B DNA in 
CSF. In addition, four patients had results just under the true positive microarray cut-off 
level: one simultaneous HHV-6A and -6B DNA (Table 10, patient 4), two HHV-6B 
DNA (Table 10, patients 5 and 6), and one EBV DNA (Table 10, patient 7). One of the 
five control subjects with a positive DNA finding was a previously healthy 28-year-old 
woman with papillitis in one eye, mild vertigo, headache, and emesis (Table 10, control 
1). Neuritis of the optic nerve was excluded. She was thoroughly examined without 
definite diagnosis. Her CSF revealed HHV-7 DNA. She recovered completely. Another 
control subject with sudden deafness had HHV-6A DNA detected in CSF (Table 10, 
control 2). She had elevated serum antibodies to Borrelia burgdorferi without CSF 
findings supporting the diagnosis of borreliosis. Her CSF albumin ratio was slightly 
elevated. One control subject with HHV-6B DNA finding was a seriously ill man with 
sepsis, cavernous sinus thrombosis, and FP (Table 10, control 3). His CSF albumin ratio 
was also elevated, indicating a possible blood-CSF barrier defect. The other two control 
subjects with HHV-6B DNA findings had vertigo and ear symptoms without borreliosis 
(Table 10, controls 4 and 5). 
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Facial palsy (FP) HHV-6 626 
(150–450) 







5 310 Not available 0.49 
Patient 3 
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HHV-6A & -6B 
312 
(150–450) 









1 0 2.82 0.31 
Patient 6 
11 































thrombosis, FP, sepsis 
HHV-6B 442 
(150–450) 
95 17 9.72 0.61 
Control 4 
8 
Vertigo, ear symptoms HHV-6B 237 
(150–300) 
0 0 2.96 0.34 
Control 5 
55 
Vertigo, ear symptoms HHV-6B 176 
(150–450) 
2 0 2.60 0.40 
 
*Leukocyte count E6/l 
†Erythrocyte count E6/l 
‡Albumin ratio = CSF albumin/serum albumin 
§IgG index = (CSF/serum IgG ratio)/(CSF/serum albumin ratio)
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Study IV  
 
The search for MRS revealed 35 patients; 29 with MRS, four with probable MRS, and 
two with possible MRS (Table 11). Patients at the Department of Dermatology all had 
labial or facial edema as a frequent or persistent symptom (Table 12). Samples of 
edematous tissues had revealed typical findings of MRS. Two of these patients also had 
FP and LP, thus, a complete form of MRS (Table 11, patients 1 and 2), all of the rest 
were monosymptomatic CG patients.  
 
All 18 patients at the Department of Otorhinolaryngology had FP and 11 had LP (Tables 
11 and 12, Fig. 5). The full triad of symptoms was found in nine patients (Table 11, 
patients 3, 5–12). MRS FP patient characteristics are shown in Table 11. Median age at 
symptom onset was 21.5 years in the FP group and 34 years in the CG group. The 
difference was not statistically significant (Mann-Whitney U-test, P = 0.26). 
 
Of the 20 patients with FP, 17 answered the questionnaire and 14 were able to attend the 
clinical examination. Two of the FP patients at the Department of Dermatology with 
persistent labial edema had previously had a tissue biopsy taken showing typical 
nonnecrotizing granulomatous infiltrations (Table 11, patients 1 and 2). For several 
years, patient 3 (Table 11) had had in the upper lip short episodes of edema, which 
gradually became more persistent. He had visited the Department of Dermatology and 
tissue biopsies were taken without specific findings. The patient was sent to an 
otorhinolaryngologist who noted LP, discovered FP, and diagnosed MRS. New tissue 
biopsies were taken during an acute edema episode, revealing nonnecrotizing 
granulomatous infiltration. Another patient (Table 11, patient 4) had had edemas 
recurring in the right cheek for a year, resolving in 5–7 days. She was also seen with an 
acute edema episode, and a tissue sample was taken with edema clinically almost 
resolved. After sample-taking, the edema worsened for few days, but then subsided. The 
tissue sample revealed nonnecrotizing granulomas consisting of histiocytic cells and 
small lymphocytes. A sample taken from six other patients (Table 11) revealed no 
specific findings. A blood sample to search for UNC-93B1 gene mutations predisposing 
to HSV-1 infection was obtained from 13 patients (Table 11); no gene mutations were 
found. 
 
In the FP group, three triad patients had constant facial edema and patient 1 (Table 11) 
had had cheiloplasty of the upper and lower lip. Even though most of the other FP 
patients had edema recorded in patient history (Table 12), it was not the dominating 
feature of the syndrome; it appeared seldom and was mostly moderate in nature. The 
first symptom of the syndrome in FP patients was FP in most cases. In the CG group, 12 
of the 15 patients had persistent edema, which had developed over the years. The most 
common site of edema in both groups was the upper lip, but both lips and cheeks were 
also common, as was the tongue. Other sites included the neck, eyelids, and larynx, and 
one patient (Table 11, patient 1) had biopsy-proven vulvitis granulomatosa. 
 
Two triad MRS patients were siblings (Table 11, patients 8 and 9), but other members 
in their family showed no signs of the syndrome. One triad MRS patient (Table 11, 
patient 7) had a father with FP, a mother with facial edemas, and siblings with LP. She 
was also a symptomless carrier of a gene mutation in chromosome 10q24 for an 
autosomal recessively inherited severe neurodegenerative disorder called infantile onset 
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spinocerebellar ataxia. One triad patient had a brother with FP (Table 11, patient 3), 
another triad patient had a sister and a grandfather with LP (Table 11, patient 2), and 
one patient had an uncle with FP (Table 11, patient 16). Two triad MRS patients had 
recurring anterior uveitis (Table 11, patients 1 and 5). Examinations did not reveal 
sarcoidosis or diseases other than MRS. Both patients were HLA-B27-negative. 
Migraine was found in 47% of the MRS FP patients answering the questionnaire. 
 
 
 Table 11. Melkersson-Rosenthal syndrome (MRS) patients (n = 20) with facial palsy (FP). 
 
 Patients 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
MRS  Proven Probable  Possible 
Gender F F M F M M F M F F F F F F M F M M F F 
Age 50 37 59 47 36 39 60 41 40 36 74 34 48 54 36 47 72 44 59 67 
Age at onset 22 10 39 12 24 21 23 31 21 21 48 15 13 47 20 43 20 44 12 67 
Number of FP 1 2 1 1 2 2 3 1 2 2 3 4 4 2 3 2 3 1 4 1 
Lingua plicata ● ● ● – ● ● ● ● ● ● ● ● – – – ◘ ● ● – – 
Facial edema ● ● ● ● ● ● ● ● ● ● ● ● ● ● x1 x1 – – ◘ ● 
Questionnaire ● ● ● ● ● ● ● ● ● ●   ● ● ● ● ●  ● ● 
Examination ● ● ● ● ● ● ● ● ●    ●  ● ●   ● ● 
Mutations* – –  – – – – – –    –  – –   – – 
Histology +/– + + + + – – – –       –     – 
 
F = female, M = male 
● = yes, ◘ = mild symptom, – = no 
*Leading to UNC-93B protein deficiency: – = mutations not found 






Table 12. Frequency of symptoms in 35 Melkersson-Rosenthal syndrome patients in 
two specialty departments. 
 
Symptom Otorhinolaryngology (n = 18) 
Number of patients (%) 
Dermatology (n = 17) 
Number of patients (%) 
Facial palsy 18 (100) 2 (12) 
Triad of symptoms
* 
9 (50) 2 (12) 
Edema 16 (89) 17 (100) 
Lingua plicata (LP) 11 (61) 2 (12) 
LP or moderately 
plicated tongue 
12 (67) 5 (29) 
 


















An objective evaluation method for everyday clinical use to grade facial function has 
not yet been developed or at least agreed upon. We assessed two subjective methods in 
Study I: H-B FGS because it is the method suggested for standard reporting of facial 
function by the Facial Nerve Disorders Committee of the AAO-HNS and SFGS because 
of its gaining popularity and the good reviews it has recently received. We discovered 
that the statistical method used to evaluate SFGS repeatability and agreement had a 
marked effect on study outcome; ICC, previously almost exclusively used to assess 
SFGS, gave excellent results in every measurement, whereas CR, suggested to be more 
reliable by Altman and Bland (1983), was not as flattering. Still our results showed that 
SFGS reliability was at least as good as H-B FGS reliability, and agreement for SFGS 
was better than that for H-B FGS. We concluded that while waiting for an ideal facial 
grading method, the usage of SFGS over H-B FGS should be encouraged. 
 
Although H-B FGS has a standard grading scale status, studies on its repeatability are 
few. Repeatability of H-B FGS was previously found to be moderate (Ahrens et al. 
1999), with unweighted kappa (considered a more appropriate statistical method than 
weighted kappa based on the material studied). Our results varied according to the 
statistical method used and were from fair (agreement %) to good (weighted kappa). 
Since weighted kappa usually gives better results than unweighted kappa, our results are 
in accordance with the earlier finding. Studies estimating agreement for H-B FGS have 
been more frequent although the number of studies is still rather low and the results 
vary. Our findings were in accordance with the poor or fair agreement results described 
in several studies (Croxson et al. 1990, Murty et al. 1994, Ahrens et al. 1999) and 
supported the view that H-B FGS is prone to interobserver variation. Others report 
reasonably good agreement results, but have reservations about H-B FGS as an 
international standard scale because of wide variations among expert assessors (Smith et 
al. 1992, Rickenmann et al. 1997, Coulson et al. 2005). One study (Evans et al. 1989) 
found agreement of H-B FGS to be very good, presenting no drawbacks in their 
discussion.  
 
Previous studies on SFGS repeatability have used ICC, and their results for composite 
score are excellent (Ross and Nedzelski 1997, Ahrens et al. 1999, Hu et al. 2001), as 
was our result by ICC. When we used CR, the result was still good, but not near-perfect 
as with ICC. Agreement between doctors for SFGS composite score in earlier studies 
has also been found to be excellent (Ross and Nedzelski 1997, Ahrens et al. 1999, 
Kayhan et al. 2000, Hu et al. 2001), consistent with our result by ICC. However, with 
CR, our result was only moderate. No previous studies using CR were found.  
 
When testing SFGS individual components, Kayhan et al. (2000) reported voluntary 
movement agreement to be very good, and resting symmetry and synkinesis agreement 
to be good (method used was kappa statistics, which is described as being equivalent to 
ICC, kappa statistics interpretation used). Coulson et al. (2005) reported agreement for 
voluntary movement to be from fair to good, but agreement for synkinesis as only poor 
by ICC. In our study, with ICC, all agreement results for individual components were 
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excellent. With CR, the voluntary movement result was good, but resting symmetry and 
synkinesis results were only moderate or fair. These findings indicate that individual 
components of resting symmetry and synkinesis are difficult for assessors to define. 
This is further supported by our repeatability CR result for individual components, 
where voluntary movement and synkinesis received good results, but resting symmetry 
only moderate results; thus, it was difficult for the assessor to even agree with 
him/herself in resting symmetry grading. No other study defining repeatability of SFGS 
individual components was found. Doctors may be more prone to define the severity of 
FP from voluntary movements, while synkinesis and resting symmetry are paid less 
attention. Using H-B FGS, this is possible. With SFGS, the severity of synkinesis and 
the resting symmetry appearance must be described in detail. Most of our resident 
assessors had used SFGS for about 1.5 years before this study, whereas most of our 
specialists were unfamiliar with SFGS, having more experience with FP patients and H-
B FGS. With beforehand preparations (SFGS teaching video, booklet outlining grading 
scales and synkinesis), however, no statistical difference was present between our 
assessor groups. SFGS has previously been reported to be used as reliably by both 
experts and novice users (Hu et al. 2001). Our novice users were the specialists. Our 
agreement results of the individual SFGS components were probably better than in the 
two forementioned studies (Kayhan et al. 2000, Coulson et al. 2005) because ICC was 
excellent and only CR showed a less than perfect outcome. This could be a result of the 
beforehand preparations, indicating that even a brief introduction is helpful in achieving 
more reliable findings.  
 
Our patient number was small (n = 8), which is a weakness of the study, but this was a 
deliberate choice to obtain as many assessors as possible. It took about 30 minutes in 
each round to assess these eight patients, and we thought that increasing the assessment 
time would diminish the number of voluntary assessors. We had 28 assessors, which is 
more than in any previous study (maximum eight). We tried to simulate a clinical 
setting; in our hospital, all doctors come into contact with FP patients and need to define 
the grade of FP, not only the doctors primarily involved with these patients. A good 
grading scale should work reliably whether the user needs it once or twice a year 
(general practitioners) or daily (FP investigators). 
 
In the current situation with no unambiguous way of expressing the facial appearance 
and function with one standard method worldwide, comparing one study with another or 
one method of treatment with another gives only approximate results, the accuracy of 
which remains uncertain. Because normal facial function is already quite variable within 
individuals, a reliable grading system is hard to develop. The first clinically affordable 
and usable objective methods will likely have cameras and computers at a fixed location 
and clinicians can order a “facial grading test”, similar to the current request for 
audiometry. While this would be a giant step from today’s clinical reality, it would not 
solve the everyday, ubiquitous need to grade facial appearance and function. SFGS is an 
easy-to-use scale with good reviews and suggestions for improvements, as discussed 








While herpesviruses are suspected etiologic factors in Bell’ palsy, confirmation remains 
elusive. With the decreasing popularity of decompression surgery as a treatment 
method, there are less studies trying to find signs of viruses directly in the facial nerve. 
Bell’s palsy is peripheral in nature, but some studies have raised suspicion of CNS 
involvement, at least in some cases (Roberg et al. 1991, Adour 2002). Some 
investigators perform decompression surgeries proximal to the geniculate ganglion in 
selected Bell’s palsy cases and simultaneously acknowledge reactivation of 
herpesviruses in the geniculate ganglion as the etiologic factor (Gantz et al. 1999). This 
supports the view of concurrent retrograde affision of the facial nerve towards CNS. We 
found no signs of DNA of HSV-1 or VZV, the two most suspected etiologic factors for 
Bell’s palsy. Instead HHV-6 and -7 DNA were observed in CSF of both FP patients and 
controls. 
 
Studies on CSF findings of peripheral FP patients are scarce. In most studies preceding 
the use of PCR, the outcome was inconclusive and abnormalities included pleocytosis 
and previously undiagnosed borreliosis (Jonsson et al. 1990, Hydén et al. 1993, Inci et 
al. 1999, Kohler et al. 1999, Birkmann et al. 2001). Later with PCR, VZV DNA has 
been found in CSF of Ramsay Hunt syndrome patients (Murakami et al. 1998, 
Stjernquist-Desatnik et al. 2006). Because all patients did not show VZV DNA, the 
hypothesis was tendered that VZV genomes disappear during the early stages of the 
disease (Murakami et al. 1998). Studies searching for HSV-1 and -2, VZV, EBV, and 
CMV DNA in CSF of Bell’s palsy patients have not succeeded in finding any DNA of 
these viruses, even when samples have been taken soon after palsy onset (Larsson et al. 
1998, Stjernquist-Desatnik et al. 2006). Many of the CSF samples had elevated white 
blood cell counts or protein levels as an indicator of inflammatory activity (Stjernquist-
Desatnik et al. 2006) and intrathecal antibodies showing a longer duration of the 
infection than indicated by symptoms (Larsson et al. 1998). In FP, the infection was 
concluded to be transient and essentially terminated by the onset of symptoms (Larsson 
et al. 1998).  
Most CSF studies on HHV-6 and -7 involve immunocompromised patients or small 
children. CSF studies on other patients, particularly FP patients, are scarce. These 
viruses have rarely been found in the CSF of immunocompetent and noncritically ill 
patients, especially adults. Previously, HHV-6 DNA was searched for and found in CSF 
of three multiple sclerosis patients, but specimens from FP patients (n = 19), Guillain-
Barré syndrome patients, and controls were negative (Wilborn et al. 1994). In Study II, 
we identified one FP patient with HHV-6 DNA. His CSF albumin ratio and protein 
level were increased, thus whether the virus DNA originated from the CNS is uncertain. 
If he had a blood-CSF barrier defect, it could have been a constant feature because of 
the poliomyelitis he had suffered as a child. This patient was later tested again by 
microarray (III), and the sample no longer yielded a positive HHV-6 DNA result. The 
reason for this discrepancy can only be speculated, but it may arise from a technical 
failure: the sample had already gone through several freezing and thawing cycles when 
tested in Study III. HHV-7 DNA has previously been found in CSF of one Bell’s palsy 
patient, a 6-year-old girl without any additional symptoms (Pohl-Koppe et al. 2001). 
Our patient with HHV-7 DNA finding was a teenager, beyond the age at which primary 
infection generally occurs. Whether she was undergoing an exceptionally late primary 
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infection or a reactivation of HHV-7 is unknown. One of our patients had a dual 
detection of HHV-6A and -6B DNA in CSF. We found no other reports of dual 
detection of these viruses in CSF.  
 
Previously, HHV-7 DNA has been found in adult CSF in three cases, none of them FP 
(Sgarabotto et al. 2000, Ward et al. 2002, Mihara et al. 2005). These patients had severe 
CNS symptoms, whereas our control subject with HHV-7 DNA had only mild 
symptoms. She showed no indication of a blood-CSF barrier defect, so HHV-7 
presumably came from the CNS. Whether the virus was an etiologic factor in her 
symptoms remains unknown.  
 
HHV-6 reactivation has been detected in critically ill but otherwise immunocompetent 
patients and during infections with other viruses (Ward 2005). One of our controls had 
severe infections, and possibly a reactivation of HHV-6B. Our control subject with 
sudden deafness could have had reactivation of HHV-6A because of underlying 
suspected borreliosis. Rising antibody titers to HHV-6 in some sudden deafness patients 
have been reported previously (Takasaki et al. 1998), and thus, an association is 
possible. Two of our control subjects with vertigo and ear symptoms had HHV-6B 
DNA in CSF, but no similar literature reports were found. The youngest subject with 
HHV-6 DNA in CSF was 8 years old, the others were adults. Therefore, the results are 
not explained by transient CSF DNA findings associated with primary infections (Ward 
et al. 2007). 
 
Our positive HHV-6 DNA results may be argued to arise from chromosomal viral 
integration. Because the studies were retrospective, we could not test whole blood or 
serum for viral DNA to compare the results. However, our positive findings for HHV-6 
DNA exceeded considerably the assumed integration prevalence in the general 
population (7% vs. ~1%) (Ward et al. 2007). Furthermore, we found DNA of HHV-7, 
which is not known to be able to integrate in chromosomes. A total of 10% of the tested 
samples contained HHV-6 or -7 DNA. 
 
In addition to the retrospective nature of our etiology studies (II, III), they were limited 
by the late timing of part of the CSF samples, and the young age of many of our study 
group patients. Limitations of our methods included an inability to differentiate active 
disease from inactive disease and our PCR method was not able to measure the DNA 
load. Strengths included the numerous CSF samples of FP patients and the very 
sensitive microarray method: the detection limit was less than 10 copies or virus 
particles. Although we could not determine the significance of HHV-6 and -7 DNA in 
CSF of FP patients or controls, we showed more frequent appearance of the DNAs in 
immunocompetent patients than could be expected. Most FP patients in our study had 
no herpesviral DNA in CSF, and this could be interpreted to speak against CNS 
involvement in peripheral FP. However, finding HHV-7 and dual HHV-6A and -6B 
DNA in CSF of FP patients is intriguing because DNA of these viruses is seldom found 
in CSF. 
 
In our clinical practice, CSF samples to exclude CNS infections are taken from all 
children with FP. Blood samples to search for signs of infections are also frequently 
tested in children. This accelerates the possibility of finding associations of FP with 
other diseases, especially viral infections, among pediatric FP patients. Adults with 
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classical monosymptomatic Bell’s palsy rarely get tested beyond exclusion of 
borreliosis by serology. Prospective CSF studies are difficult to arrange in 
uncomplicated adult FP patients. More thorough testing of adults, both serum and CSF, 
would probably yield associations with other diseases, perhaps shedding light on the 
path to solving the mystery of FP etiology and, in doing so, also the proper management 






As a rare disorder of unknown etiology, undefined incidence, and inconsistent definition 
and classification, the diagnosis of MRS is based on the alertness of the physician. We 
studied 35 patients with MRS or suspicion of it at the Departments of Dermatology and 
Otorhinolaryngology and found that the clinical picture of the disease varied greatly 
according to the department specialty where the patient was treated. All patients at the 
Department of Otorhinolaryngology (n = 18) had FP in patient history, whereas only 
two at the Department of Dermatology did, with the remaining 15 patients having 
monosymptomatic CG. These results support our hypothesis that the existing 
knowledge on MRS might be influenced by most published studies being from the 
departments of dermatology and oral and plastic surgery dealing with MRS patients 
troubled by edemas. Studies from departments of otorhinolaryngology are rare, and 
patients with FP the clear minority. Monosymptomatic CG patients have received the 
most attention in the literature. 
 
MRS affects all age groups, but the most common time of onset is often stated to be the 
second decade of life or young adulthood. From studies with more than a few patients, 
the (median or mean) onset age is higher, 25–40 years (Rintala et al. 1973, Worsaae et 
al. 1982, Hornstein et al. 1987, Greene and Rogers 1989, Zimmer et al. 1992), 
consistent with our age median of 24 years. We had twice the number of females 
compared with males in our study; the gender ratio has varied markedly in previous 
studies (Rintala et al. 1973, Worsaae et al. 1982, Hornstein et al. 1987, Zimmer et al. 
1992).  
 
In the literature, the most common initial symptom is edema (Rintala et al. 1973, 
Worsaae et al. 1982, Hornstein et al. 1987, Zimmer et al. 1992), and the same was true 
in our study when considering patients from both departments. Among patients with FP, 
the most common initial symptom was FP, which has also been reported previously 
(Greene and Rogers 1989). The most common site for edema is the upper lip both in the 
literature (Rintala et al. 1973, Worsaae et al. 1982, Hornstein et al. 1987, Zimmer et al. 
1992) and in our study. Edema is considered to be the most frequent and dominating 
feature, eventually affecting almost all MRS patients and gradually becoming persistent 
(Hornstein et al. 1987, Greene and Rogers 1989). This was the case with our patients at 
the Department of Dermatology, but even though most of the patients at the Department 
of Otorhinolaryngology had edema in patient history, it tended to be moderate in 
severity, appeared seldom, and no signs of progression were seen. FP episodes in MRS 
have also been postulated to gradually last longer or become permanent (Zimmer et al. 
1992). In our patients, the palsies did not last longer, nor did they come permanent, 
although more then half of the examined patients had residual symptoms from FP.  
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FP is estimated to appear in 20–30(–50)% of all MRS cases, and the triad form in up to 
20% of cases (Hornstein 1973, Rintala et al. 1973, Worsaae et al. 1982, Hornstein et al. 
1987, Zimmer et al. 1992, van der Waal et al. 2002). In our study, with both 
departments combined, FP was present in over half of the patients and the triad form in 
one-third of all cases, which is higher than in previous reports. If we consider only the 
patients treated at the Department of Otorhinolaryngology, every patient had FP and 
half had the triad form. This supports our hypothesis that the existing knowledge on the 
clinical picture of MRS may be influenced by most published studies being from 
departments treating patients with edemas. In our study, with both departments 
combined, one-third of patients had LP. This is less than the reported average of about 
half of MRS patients having LP (Rintala et al. 1973, Worsaae et al. 1982, Hornstein et 
al. 1987, Zimmer et al. 1992). Most patients at the Department of Dermatology being 
monosymptomatic CG patients and mildly fissured tongues not being included in the 
count explains our low LP incidence.  
 
MRS is sometimes associated with herpes infection type blisters at the beginning of 
edema (Hornstein 1973, Worsaae et al. 1982, Ziem et al. 2000), and two of our patients 
reported reappearing blisters on the tongue. Herpesvirus etiology has been suggested in 
MRS as well as in Bell’s palsy (Ziem et al. 2000). We searched for single-gene 
mutations that would lead to UNC-93B protein deficiency and susceptibility to HSV-1 
infection, but detected no signs of this. These mutations have been described in 
otherwise healthy children with HSV-1 encephalitis (Casrouge et al. 2006). None of our 
patients had serious infections recorded in their patient histories. 
 
Typical MRS histology shows nonnecrotizing lymphoepitheloid granulomatous 
infiltrations, which may also be replaced by small lymphoplasmocytic clusters or 
mononuclear infiltrates surrounding small vessels (Hornstein 1997). In our study, 
patients at the Department of Dermatology all had histology-proven CG (n = 15) or 
MRS (n = 2). One MRS FP patient with slight persistent upper lip edema had unspecific 
previous biopsy results, but a new sample taken during an acute edema episode revealed 
nonnecrotizing granulomas. If edema is already persistent, repeated biopsies are 
recommended because negative histology findings in typical clinical MRS are common 
(Zimmer et al. 1992). It has been speculated that granulomatous infiltrations can only 
develop in advanced disease with persistent edema (Greene and Rogers 1989). Another 
MRS FP patient had recurring edemas, not persistent, of the cheek for only one year, but 
revealed nonnecrotizing granulomas in a tissue sample taken during an acute edema 
episode. Typically, edema periods had lasted 5–7 days and edema was almost resolved 
on the sixth day when the biopsy was taken. New activation of the edema was observed 
following the biopsy for three days, but resolved again. Tissue samples taken from six 
other patients without persistent edema were unspecific. These results encourage timing 
biopsies to acute edema periods. Most of the MRS patients at the Department of 
Otorhinolaryngology had mild edema symptoms, attacks were far apart, and the patients 
had never visited a doctor because of their edema. Emphasizing the importance of 
edema in MRS diagnosis (Hornstein 1997) might underestimate the number and forms 
of MRS patients treated at otorhinolaryngology departments. 
 
Two of our patients had reappearing acute anterior uveitis, and one earlier report was 
found of the association (Ates and Yoruk 2006). This could be due to immunologic or 
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autoimmune disturbances considered among possible etiologic factors in MRS 
(Hornstein 1997). In our study, migraine was common among MRS FP patients, as also 
demonstrated previously (Hornstein et al. 1987), but incidences comparable with those 
of the general population exist as well (Vistnes and Kernahan 1971, Greene and Rogers 
1989). Two of our triad patients were siblings and four other FP MRS patients had a 
relative with FP or LP. This is in accordance with the knowledge of a somewhat 
increased risk of MRS in relatives, especially first-degree relatives (Meisel-Stosiek et al. 
1990). One of our patients was a gene mutation carrier (chromosome 10q24) for 
infantile onset spinocerebellar ataxia. One previous publication with an MRS patient as 
a carrier of balanced de novo 9p/21p translocation and her child with unbalanced 9p 
trisomy (without MRS symptoms) has been published with the conclusion that MRS has 
autosomal dominant inheritance with variable expression and gene 9p11 could be the 
location (Smeets et al. 1994). We consider these mutations coincidental. 
 
In our study, we probably missed some MRS patients. At the Department of 
Dermatology, only histology-proven cases were coded under MRS and were found by 
computer search. At the Department of Otorhinolaryngology, MRS diagnosis is not easy 
because symptoms most often appear at different times and far apart from each other. If 
an FP patient presents with a deeply grooved LP, the connection to MRS is made easier. 
Since only half of the MRS patients have LP, many MRS patients probably have not 
been diagnosed, especially if their edemas are mild and appear seldom. Every FP patient 
should be asked about oro-facial edemas, especially if FP has reoccurred. Although 
treatments of MRS are often unsatisfactory, patients are usually relieved to get a 
diagnosis, tying the odd separate symptoms together. A broader view of the clinical 
picture, the true incidence, and perhaps data enabling the etiology of MRS to be solved 
could potentially emerge from the accumulation of information from different 
specialties. At otorhinolaryngology departments, probably more MRS patients with FP 






1. SFGS proved to be at least as good as, if not better than, H-B FGS in repeatability 
and was more reliable in agreement. The usage of SFGS can thus be recommended 
over H-B FGS. 
 
2. HHV-7 and dual HHV-6A and -6B DNA, rare findings in any patient, were found in 
CSF of FP patients. Since DNA of HHV-6A, -6B, and -7 was also found in CSF of 
control subjects, the significance of the results in association with the diseases they 
accompany was not established. The abundant finding of HHV-6 or -7 DNA in the 
CSF of about 10% of evaluated immunocompetent adolescents and adults without 
severe diseases was markedly higher than expected, suggesting caution when 
interpreting CSF findings. No CSF of patients or controls had DNA of HSV-1 or 
VZV, the most suspected etiologic factors for Bell’s palsy. 
 
3. The clinical picture of MRS varied according to department specialty; every MRS 
patient at the Department of Otorhinolaryngology had FP, and edema was mostly 
not progressive and did not dominate the clinical picture, contrary to existing 
knowledge and to those patients treated at the Department of Dermatology. Among 
MRS patients with FP, the triad form of MRS was very common. Our findings 
support taking tissue biopsies during acute edema episodes to reveal nonnecrotizing 
granulomatous infiltrations. We found no UNC-93B1 gene mutations predisposing 
to HSV-1 infections. Two triad MRS patients had recurring acute anterior uveitis; an 
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Oligonucleotides Gene name Sequences (5’→ 3’) Position 
HSV-1, X14112 HSV-FW DNA pol. AAGGAGGCGCCCAAGCGCCCG 64750–64768 
 HSV-RV  AATTAACCCTCACTAAAGGGAGA 
TGGGGTACAGGCTGGCAAAGT 
64976–64956 
 HSV-1-T3  Am-TTTTTTTTTGTCCTTGACCCCACTT 64907–64922 
HSV-2, Z86099 HSV-FW DNA pol., UL30 AAGGAGGCGCCCAAGCGCCCG 65209–65229 
 HSV-RV  AATTAACCCTCACTAAAGGGAGA 
TGGGGTACAGGCTGGCAAAGT 
65449–65429 
 HSV-2-T3  Am-TTTTTTTTTAGGATAAGGACGACGAC 65279–65295 
VZV, AY548171 VZV-FW DNA pol., ORF28 CCATTTTCTCGCCGATTTTA 48508–48527 
 VZV-RV  AATTAACCCTCACTAAAGGGAGA 
GCCGCATTTGAACGTTTTAT 
48670–48651 
 VZV-T3  Am-TTTTTTTTTACCTCGTACGCTTTTTG 48597–48613 
CMV, AY446894 CMV-FW DNA pol., UL44 GTACAACAGCGTGTCGTGCT 57044–57063 
 CMV-RV  AATTAACCCTCACTAAAGGGAGA  
CACCGGCCATCAAGTTTATC 
57240–57221 
 CMV-T3  Am-TTTTTTTTTGTAGAAGTTCTTCAGCTGC 57122–57140 
EBV, AJ507799 EBV-FW DNA pol., BALF5 CGTAGATGACTCGAAGCTG 154029–154047 
 EBV-RV  AATTAACCCTCACTAAAGGGAGA  
ACCATCCTCGACAAGCAG 
154278–154261 
 EBV-T3  Am-TTTTTTTTTGAGAGGCAGGGAAAGAGG 154184–154201 
HHV-6A, X83413 HHV-6-FW DNA pol., U38 CTCGATCGAATCCGTAAACA 59289–59308 
 HHV-6-RV  AATTAACCCTCACTAAAGGGAGA 
CCGCGTATGTTTTATCGAGAC 
59444–59424 
 HHV-6A-T3  Am-TTTTTTTTTATCCTTGGACCGAGCTA 59361–59377 
HHV-6B, AF157706 HHV-6-FW DNA pol., U38 CTCGATCGAATCCGTAAACA 60409–60428 
 HHV-6-RV  AATTAACCCTCACTAAAGGGAGA 
CCGCGTATGTTTTATCGAGAC 
60564–60544 
 HHV-6B-T3  Am-TTTTTTTTTATCCTTGGACCGAACTC 60481–60497 
HHV-7, AF037218 HHV-7-FW DNA pol., U38 AGGTCCAACATGCACAGTGA 56787–56806 
 HHV-7-RV  AATTAACCCTCACTAAAGGGAGA 
GGCAAAGAAAATGTGGGCTA 
56993–56974 
 HHV-7-T3  Am-TTTTTTTTTGGATACAAACTTTGGAA 56893–56909 
FW, forward primer (sense); RV, reverse primer (anti-sense, T3 RNA polymerase promoter sequence AATTAACCCTCACTAAAGGGAGA 
before virus sequence); T3, oligonucleotide (sense, 9 T spacer arm before sequence); Am, amino-link. 
